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Abstract 
 
  Modified nucleosides form an important class of antiviral and anticancer agents, and 
nucleic acids bearing modified nucleosides hold great promise as therapeutic agents. Oxepane 
nucleosides and nucleic acids are members of this important class of compounds. Oxepane 
nucleosides have a seven-membered carbohydrate ring instead of the canonical five-membered 
pentafuranose ring. This thesis describes work in the development of new synthetic approaches 
and routes in the synthesis of oxepane nucleosides. In chapter 2, the synthesis of oxepane 
nucleosides based on the ring expansion approach is described. Building on previous work in the 
Damha lab, studies in the synthesis of oxepane nucleosides by a ring expansion approach were 
carried out. In particular, oxepane nucleosides were synthesized using thioglycoside derivatives. 
Routes in the modification of the oxepane scaffold were explored, but later abandoned in favor 
of new synthetic approaches to oxepane nucleosides.  
 In chapter 3, work towards the development of new routes in the synthesis of oxepane 
nucleosides by ring-closing metathesis is described. This new approach to the synthesis of 
oxepane nucleosides allows for the use of commercially-available nucleosides and circumvents 
the difficulties observed in glycosylation reaction employed in the previous approach. In chapter 
3, various synthetic routes are examined, and work towards the development of viable routes is 
described. In particular, the direct addition of Grigard reagents to nucleosides dialdehydes, 
followed by Grubbs II mediated ring closing metathesis serves as a proof-of-principle of the 
synthesis of oxepane nucleosides by a ring closing route.  
 
 
iv 
 
Abrégé  
 
 Les nucléosides modifiés sont des agents thérapeutiques très efficaces contre le cancer et 
contre des virus.  Les oxepanes font partie de ce groupe important. Au lieu d’avoir un cycle de 5 
atomes, les oxepanes ont un cycle modifié de 7 atomes. Cette thèse décrit la recherche sur le 
développement de nouvelles méthodes pour la synthèse des oxepanes. Dans le deuxième chapitre, 
la synthèse des oxepanes par la méthode d’expansion de cycle est traitée. Notamment, la synthèse 
des oxepanes par le biais des hétérosides contenant des thiols est décrite. Dans le troisième 
chapitre, de nouvelles méthodes pour la synthèse des oxepanes sont étudiées. Toutes ces 
approches ont pour but ultime d’utiliser la métathèse d’alcènes comme l’étape clé. Notamment, 
l’addition directe des réactifs de Grignard à des nucléosides contenant deux aldéhydes, suivi 
d’une métathèse d’alcène, constitue une démonstration de faisabilité de cette approche 
synthétique.  
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Chapter 1 Introduction 
 
1.1 Structure and Function of Nucleic Acids 
1.1.1 Discovery of Nucleic Acids 
 
Nucleic acids were first discovered by Friedrich Miescher, a Swiss physician, in 1868. 
While this new substance was initially found in human leukocytes that were taken from used 
surgical bandages,1 nucleic acids were later found in other cell types. Indeed nucleic acids are 
essential components found in the cells of all organisms on Earth. Almost a century would 
pass, however, before the biological role and significance of nucleic acids would be 
understood. Up until the beginning of the 1940s, the seeming simplicity of nucleic acids led 
most biologists to assume that they played only a relatively minor in the body. However, in 
1944 Oswald Avery, in a seminal publication, laid the foundations for our understanding of 
DNA as the carrier of genetic information.2 Within a decade of this publication, the double 
helical structure of DNA3 was elucidated by Watson and Crick with the indispensable help of 
Rosalind Franklin and Maurice Wilkins. 3,4 
1.1.2 Structure of Nucleic Acids 
 
 DNA is a linear polymer comprised of four basic building blocks, which are shown 
in figure 1.1. Deoxyadenosine, 1.1, and deoxyguanosine, 1.2, are the purine nucleosides; 
deoxycytidine, 1.3, and thymidine (or deoxythymidine), 1.4, are the pyridine nucleosides.  
RNA is constituted of similar subunits, also shown in figure 1.1. In fact, the key structural 
difference is the sugar component. Instead of D-2-deoxyribose, RNA incorporates D-ribose 
as its sugar moiety. This subtle structural feature has profound implications on the chemical 
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properties and biological function of RNA. The nucleobases of adenosine, 1.5, guanosine, 
1.6, and cytidine, 1.7 are identical to their DNA counterparts. Only the nucleobase of uridine, 
1.8, is different from its DNA analogue, lacking a methyl group at the C5-position (figure 
1.1). 
 
 
Figure 1.1 Structures of Nucleosides. Structures 1.1-1.4 are the basic building blocks of 
DNA. Structures 1.5-1.8 are the basic building blocks of RNA.  
 
 
To facilitate discussion of structure, nucleosides are assigned a standard numbering 
system. For all nucleosides, the carbon atoms of the pentose sugar moiety are numbered 
using primed numbers, shown in red in figure 1.2. This numbering starts at the carbon 
bearing the glycosidic linkage, known as the anomeric carbon, and increases in a clockwise 
fashion. Numbering of the nitrogenous base is more complex and depends on the class of 
the nucleobase. For the bicyclic purines, as in the case of 1.5, numbering begins at one of the 
nitrogen atoms in the six-membered, shown in blue, and proceeds until all the atoms have 
been numbered. In this system, the nitrogen atom directly attached to the sugar moiety is 
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labeled as atom 9.  For the monocyclic pyrimidines, as in the case of 1.8, numbering begins at 
the nitrogen involved in the glycosidic bond and proceeds in a counterclockwise fashion 
around the ring. 
 
Figure 1.2 Numbering of purine and pyrimidine nucleosides. Adenosine, 1.5, is shown as 
representative purine. Uridine, 1.8, is shown as a representative pyrimidine.  
 
 When a phosphate group is attached to the 5' or 3' oxygen, the compound is referred 
to as a nucleotide. These compounds are the repeating units, or monomers, of DNA and 
RNA. Polymers of nucleic acids are formed by a phosphodiester linkage between adjacent 
nucleotide subunits. In both DNA, 1.9, and RNA, 1.10, this linkage is formed using the 5' 
hydroxyl of one nucleotide and the 3' hydroxyl of another nucleotide, as shown in figure 1.3. 
The sequence of the nucleotides in a strand of DNA or RNA is referred to as the primary 
structure. Complimentary strands of nucleic acids self-assemble to form the iconic double 
helix, which is the secondary structure. Hydrogen bonding between complementary 
nucleobases and hydrophobic stacking of the bases drive this spontaneous process. Watson-
Crick base pairing of the nucleobases follows a consistent pattern that was initially 
discovered by Watson based on ratios observed by Chargaff. Adenine pairs with thymine, 
cytosine pairs with guanine.5 In the case of RNA, thymine is replaced by uracil and the base 
pairing relationships are the same. This complementary base pairing, as was famously noted 
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by Watson and Crick, is the molecular basis for the storing and copying of genetic 
information.3,6 
 
Figure 1.3 Primary structure of DNA, 1.9,  and RNA, 1.10. The 2' hydroxy groups in 1.10 
greatly alter the chemical and biological properties of RNA.  
 
 While DNA’s secondary structure is the famous double helix, the actual shape, 
structure and parameters of the helix vary depending on conditions. Under low salt 
concentration and under high humidity, a form known as B-DNA, in figure 1.4,  the most 
commonly found form of double stranded DNA, is observed. In contrast, under high salt 
and low humidity, A-DNA, in figure 1.4, is favoured. Both B-DNA and A-DNA are right-
handed helices, though they differ in other helical parameters. For example, B-DNA has 10 
residues per turn, while A-DNA has 11. Differences in the widths of the major and minor 
grooves are also observed.7 For example, alternating GC duplexes of B-DNA have wide and 
shallow major grooves (width of 11.4 Å and a depth of 4.0 Å) and a narrow and deep minor 
groove (width of 5.9 Å and a depth of 5.5 Å). In contrast, alternating GC duplexes of A-
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DNA have narrow and deep major grooves (width of 2.2 Å and a depth of 9.5 Å) and a wide 
and shallow minor groove (width of 10.9 Å and no defined depth).8 The major groove 
parameters of nucleic acids are important since most DNA binding proteins interact through 
this structural feature. A third double helical conformation, called Z-DNA,  is known to 
occur. Z-DNA is distinguished by its left-handed helical twist and exists only as a transient 
conformation in biological systems.9 
 
                                                             
  
    B-DNA                                                                                     A-DNA 
 
Figure 1.4 Double helical structures of DNA. B-DNA is the most commonly observed form 
of DNA found in biological systems. Both structures are 16 nucleotides in length. Images 
generated with Spartan '08 Version 1.2.0.  
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1.1.3 Function of Nucleic Acids 
 
 In living organisms, the genetic code essential for the transmission of hereditary 
information is stored in DNA. Base pairing between nucleobases allows for the template-
directed replication of nucleic acids by polymerases.10,11 Genetic information flows from 
DNA to mRNA to protein, a process referred to as the central dogma of molecular biology, 
which was first described by Crick in 1958.12 The biosynthesis of proteins, the cell’s 
molecular machines, is directed by the sequence of nucleotides found in genes. This process 
is initiated by the transcription of DNA, found in the nucleus in eukaryotic cells, into mRNA, 
which is then exported into the cytoplasm. Ribosomes, large complexes of protein and RNA, 
translate the mRNA into a nascent polypeptide with the aid of tRNA molecules.13 
 While the storage of genetic information is ostensibly the most important role nucleic 
acids play, they have many other functions. For example, mRNA acts as a liaison between 
the DNA, located in the nucleus, and the ribosomes located in the cytoplasm. RNA in the 
ribosome14 is responsible for the catalytic activity of this organelle. Moreover, t-RNA 
molecules act as adapters, allowing the genetic code to be translated into proteins.  
 
1.2 Synthesis of Nucleic Acids 
1.2.1 Biochemical Synthesis of Nucleic Acids 
 In living systems, nucleic acids are synthesized by a class of enzymes known as 
polymerases in a semiconservative process. Cells achieve this process by the template-
mediate addition, catalyzed by polymerases, of nucleoside triphosphate monomers to the 
growing DNA strands. DNA polymerases add nucleotides in a 5' to 3' direction. Since the 
two strands in duplex DNA are antiparallel, this means that replication proceeds differently 
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on the two strands. On the leading strands, replication proceeds continuously in the direction 
of replication fork movement. On the lagging strand, however, replication proceeds 
discontinuously as Okazaki fragments,15 which are eventually joined together by the action of 
DNA ligase enzymes. 
1.2.2 Chemical Synthesis of Nucleic Acids 
 
 Chemical synthesis of nucleic acids in the laboratory started with humble beginnings:  
In the 1950s, the first dinucleotide was synthesized by A.M Michelson and Sir Alexander R. 
Todd (University of Cambridge).16 By the 1970s the first total synthesis of a yeast tRNA gene, 
by the phosphodiester method, had been reported by H.G. Khorana.17,18 Modern synthesis of 
nucleic acids involves the use of phosphoramidite chemistry19 and solid-phase synthesis20, 
shown below in figure 1.5.  
 
 
Figure 1.5 Solid-phase Synthesis Cycle.   
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 Solid-phase synthesis of nucleic acids starts with a 5' protected nucleoside tethered to 
a solid support. Deprotection of the 5' hydroxyl group with 3% trichloroacetic acid (TCA) in 
dichloromethane (DCM) initiates the cycle. Coupling of the tethered nucleoside and an 
incoming phosphoramidite, catalyzed by 4,5-dicyanoimidazole (DCI), is then carried out. 
Next a capping step, employing acetic anhydride, pyridine and N-methylimidazole (NMI) is 
carried out to block the hydroxyl groups of any unreacted components in the mixture. Once 
capping has been carried out, an Arbuzov-type oxidation of the phosphorous is effected with 
an aqueous solution of iodine, altering the oxidation state of the phosphorous from a P(III) 
to a P(V) species. Finally, the cycle can be repeated in an iterative fashion to grow 
oligonucleotides of a desired length. Alternatively, sequential deprotection of the 5' hydroxyl, 
with TCA in DCM, and the phosphate protecting groups, with an ammonium hydroxide 
solution can be carried out at this point. Treatment with ammonium hydroxide also cleaves 
the nascent oligonucleotide from the solid support, thus ending the solid-phase synthesis 
cycle. Synthesis of RNA oligonucleotide can also be achieved by adding additional 
protection/deprotection steps. Protection of RNA’s 2' hydroxyl group is commonly effected 
by the use of the tert-butyldimethylsilyl (TBDMS) protecting group. The TBDMS protecting 
group was first introduced in 1972 by E.J. Corey21 as a general protection method for 
hydroxyl groups, and later it was employed as a specific protection method in the context of 
oligonucleotide synthesis by K.K. Ogilvie.22 In the case of both DNA and RNA 
oligonucleotide synthesis, cytidine, adenosine and guanosine also need to be protected. To 
protect exocyclic amine groups of cytidine and adenosine, the benzoyl protecting group is 
used. To protect the exocylic amine of guanosine, the isobutyryl group is used.23 Under 
normal solid-phase synthesis conditions, the N3 imido functions of uridine and thymidine do 
not require protection.  
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1.3 Nucleic Acids and Nucleoside Analogues as Therapeutics 
 
1.3.1 Antisense Therapeutics 
 
 The potential of nucleic acids as therapeutic agents was first discovered by Paul 
Zamecnik in 1978 when he observed that replication of the Rous sarcoma virus could be 
inhibited by the use of an antisense oligodeoxynucleotide.24 Antisense therapeutics involves 
targeting the expression of aberrant gene products with a complementary oligonucleotide. 
The antisense pathway is show below in figure 1.6.  
 
 
Figure 1.6 Antisense pathway of gene silencing. Antisense oligonucleotides can silence genes 
by activating RNase H or by acting as a steric block to translation. Figure adapted from.25  
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 Once exported to the cytoplasm, mRNAs are normally translated into proteins. For 
normal gene products, this process is crucial for the production of essential gene products, 
such as enzymes, receptors and structural proteins. In the case of aberrant gene products, 
however, the expression (or overexpression) can lead to disease. The antisense approach to 
therapeutics involves attacking deleterious mRNAs before they can be translated into 
disease-causing proteins. In general, the antisense pathway can block translation by two 
mechanisms. In the enzyme-active mechanism, the antisense oligonucleotide binds to the 
target mRNA and recruits RNase H, which degrades the RNA strand in the heteroduplex. 
The antisense strand does not get cleaved by the RNase H enzyme, and is freed up upon 
RNA degradation.  This allows the antisense strand to bind to another mRNA strand, and 
hence promote the cleavage of several target mRNA molecules.   In the enzyme-inactive 
mechanism, the antisense oligonucleotide binds to the target mRNA and acts as a steric 
block to translation. While antisense therapeutics is an elegant approach to silencing genes, it 
has thus far led to the development of only one approved drug. In 1998, the FDA approved 
Vitravene, a phosphorotioate DNA antisense, for the treatment of cytomegalovirus 
infections.26 Despite this modest success, antisense oligonucleotides still hold great potential 
as therapeutic agents. Currently, there are many ongoing clinical trials involving 
oligonucleotides that underscore this potential. For example, Isis Pharmaceuticals has 
developed an antisense drug, mipomersen, that is currently in Phase III clinical trials.27 
Mipomersen is an anti-cholesterol drug that targets apolipoprotein B (ApoB).  
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1.3.2 RNA Interference 
 While working with the nematode worm caenorhabditis elegans, Fire and Mello 
discovered the phenomenon of RNA interference.28 RNAi is a natural gene silencing 
pathway that is triggered by double-stranded RNA, and is shown in figure 1.7.  Long double-
stranded RNA is processed into duplexes of between 21 to 23 nucleotides in length by an 
enzyme called dicer. These shorter double-stranded duplexes, called short interfering RNA 
(siRNA), then recruit the RNA-induced silencing complex (RISC), a larger protein complex. 
Cleavage of the target then ensues by the action of argonaute 2 (ago2), an enzyme found in 
the RISC complex.29  
 Currently, there are several clinical trials employing RNAi drugs, and some of the 
candidates have advanced to phases of human clinical trials. For example, bevasiranib, a drug 
targeting VEGF-A, is currently in phase III and could eventually make it to the clinic, where 
it would help those suffering from age-related macular degeneration.30 RNA interference 
holds great potential as a therapeutic tool, but it faces several hurdles. Stability of RNA 
oligonucleotides introduced into systemic circulation is problematic, and so a host of 
modification have been introduced, such as FANA, 2'OMe-RNA, and LNA.27 However, the 
greatest obstacle to RNA interference is undoubtedly delivery. The phosphodiester backbone 
of oligonucleotides is negatively charged, a fact that makes the cellular uptake of RNAi drugs 
difficult. To overcome this problem a number of delivery vehicles have been developed, 
which often involve lipid nanoparticles.27,31 While RNA interference does not yet have the 
wide applicability that traditional small-molecule drugs enjoy, RNAi therapeutics has the 
potential to revolutionize medicine.  
12 
 
 
Figure 1.7 RNA interference silencing pathway. Double stranded RNA is processed by an 
enzyme called dicer. The resulting siRNA is loaded into the RISC complex where the action 
of argonaute 2 cleaves the mRNA. Figure adapted from.29  
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1.3.3 Nucleoside Analogues as Therapeutic Agents 
 
 Nucleoside analogues have been studied intensely since the 1960s and have been a 
very successful class of antiviral compounds. During this time, many structural modifications 
have been examined and explored in the search for new medicinal compounds. Even though 
this area has been studied for so long, there is still great potential for the development of 
new therapeutic agents based on modified nucleoside analogues.  
Differences in cellular division activity between healthy and diseased cells allow for 
the therapeutic targeting by nucleoside analogues. Most cells in the body are in the G zero 
period of the cell cycle, a phase of quiescence and inactivity with respect to DNA 
replication.32 In contrast, cancer cells and viruses are continually replicating and can thus be 
targeted by chemotherapeutic agents. Once inside the cell, nucleoside analogues are 
phosphorylated and converted into 5' triphosphate derivatives. Incorporation of these 
analogues into nascent nucleic acid strands leads to chain termination. Because viral 
polymerases discriminate less effectively between phosphorylated nucleoside analogues and 
their natural counterparts, nucleoside analogues are particularly effective as antiviral agents. A 
range of nucleoside analogues are used in the treatment of diseases caused by HCMV, HSV, 
HBV, HCV and HIV infections.33 Figure 1.8 shows nucleoside analogues that have been 
approved as antiviral therapeutic agents. As can be seen in figure 1.8, nucleoside analogues 
come in many varieties. Some nucleoside analogues are acyclic (i.e., devoid of a cyclic sugar 
moiety), such as acyclovir and ganciclovir. Others have carbocyclic rings, such as abacavir 
and entecavir. Another interesting class of nucleoside analogues employs L-nucleosides, 
instead of the natural D-nucleosides. Successful antiviral compounds exhibiting this 
unnatural configuration include lamivudine (3TC) and emtricitabine (FTC).  
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Figure 1.8 Nucleoside Analogues used in the treatment of viral infections. Figure adapted 
from33 
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Chapter 2 Synthesis of Oxepanes by Ring Expansion 
 
 
2.1 Introduction 
 
 Oxepanes and oxepenes, seven-membered oxacycles, are found in a number of 
natural products such as zoapatanol,34,35 rogiolenyne,36,37 ciguatoxin38 and brevenal.39 In nature, 
however, the sugar components of nucleic acids are comprised exclusively of ribose and 
deoxyribose, five-membered oxacycles. These observations inspire us to ask interesting 
questions: Can nucleosides with larger sugar rings be synthesized? If they could be 
synthesized efficiently, what properties would they have? In turn, these questions motivate 
the study of ring expansion in nucleic acids, and the subsequent effects on the biophysical 
and medicinal properties of these nucleoside analogues. In this chapter, the synthesis of 
oxepane nucleic acids via ring expansion of cyclopropanated glycals is discussed. 
 
 
 
 
Figure 2.1 Even though five and six membered rings are more common in nature, there are 
instances of compounds containing an oxepane moiety. Brevenal and rogiolenyne are two 
examples of natural products containing seven-membered oxacyclic rings.  
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2.1.1 Early Work on Oxepane Nucleic Acids 
 
Oxepane nucleic acids were first synthesized by Dr. David Sabatino, a former 
member of the Damha group. Earlier work in the Damha group indicated that the increased 
flexibility of the oligonucleotide backbone led to an increase in RNase H activity and a 
consequent increase in antisense gene silencing.25,40 Based on these findings, a logical (though 
not obvious) approach to the development of antisense therapeutics would involve the 
synthesis of ring-expanded nucleoside analogues, which would be unconstrained and thus 
able to elicit RNase H activity. Since six-membered nucleosides had already been synthesized 
by Eschemoser,41 and their cyclohexane-like structure was less flexible relative to furanose 
nucleosides, the next logical choice for ring expansion was a seven-membered ring. 
Following this logical progression, Sabatino synthesized oxepane nucleic acid analogues of 
thymidine and adenosine, shown below in figure 2.2, and indeed found that oxepane nucleic 
acids induced RNase H activity.42 In particular, duplexes comprised of oligomers of oxepane 
2.2 hybridized to oligomers of riboadenosine elicited RNase H cleavage of the RNA strand, 
albeit at a slower rate than thymidine oligomers. Promisingly, it was also noted that oligomers 
of both oxepanes 2.2 and 2.4 were much more resistant to nuclease degradation than DNA 
oligomers. 
 
Figure 2.2 Structures of ring expanded analogues to natural DNA.  Oligomers derived from 
oxepanes 2.2 and 2.4 were shown to be more nuclease resistant than their natural DNA 
counterparts. When elaborated into oligonucleotides, oxepane 2.2 was shown to elicit RNase 
H activity. 
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Even though the ring-expanded oxepanes elicited RNase H activity and were 
nuclease resistant, they suffered from low binding affinity to their complementary 
oligoribonucleotide strands. For example, the melting temperatures of oxepane 
2.2/riboadenosine duplexes (15mers) were found to be 13 ºC. In contrast, the analogous 
DNA/RNA duplexes had melting temperatures of 37 ºC. Since the normal human body 
temperature of 37 ºC is much higher than the melting temperature of the oxepane/RNA, 
improvement in the duplex stability is critical in the development of oxepane nucleic acids 
(ONAs) as antisense gene silencing agents.  
 
2.1.2 Proposed Modifications to Location of the Phosphodiester Backbone 
 
 One factor that could impact the melting temperatures of ONA/DNA duplexes is 
the location of the internucleotide linkage, shown below in figure 2.3. Shifting the location of 
the phosphodiester backbone, we surmised, could lead to an increase in duplex stability.  
The initial thrust of the project was to synthesize the series of dihydroxylated series 
of oxepane analogues shown below in figure 2.4 and study their biophysical and medicinal 
properties. Along the way, however, the project became more focused on developing novel 
strategies and routes for the synthesis of oxepane nucleic acids in general. Because many of 
the intermediates in later synthetic schemes (Chapter 3) are novel compounds, it should be 
noted that oxepane nucleic acids hold promise not only as antisense gene silencing agents, 
but also as potential antiviral and anticancer agents. From this vantage point, the 
development of synthetic routes for oxepane nucleic acids can be seen to be of central 
importance in the exploration of their therapeutic potential. 
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Figure 2.3 Schematic showing the location of the phosphodiester backbone in oxepanes and 
natural DNA oligonucleotides. In the modified ONA 2.5, the location of the phosphodiester 
backbone, in relation to the nucleobase, differs from natural DNA, as shown in 2.6. Moving 
the location of the internucleotide linkage, as in 2.7, could lead to ONA:RNA duplexes of 
increased stability. 
 
  
 
Figure 2.4 Initial synthetic targets of the research project. By varying the location of the 
secondary hydroxyls systematically, the effects on duplex stability of ONA/RNA hybrids 
could be studied.  
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2.2 Synthesis of ONA via Ring Expansion of Cyclopropanated Glycals 
 
2.2.1 Overview of ONA Synthesis Using Cyclopropanated Glycals 
 
 The synthesis of compounds containing an oxepane moiety via ring expansion of 
cyclopropanated glycal derivatives was first carried out by John O. Hoberg, a carbohydrate 
chemist at the University of Wyoming, in the late 1990s.43 Years later this approach was first 
exploited by the Damha group to synthesize oxepane nucleosides, as shown below in scheme 
2.1. 42 
Starting from peracetylated D-glucal, the oxepine monomer 2.15 can be synthesized 
in six steps. The peracetylated D-glucal starting material, 2.9, is deprotected in a simple 
transesterification reaction employing sodium methoxide in methanol, yielding D-glucal, 2.10, 
in 99% yield. In turn, D-glucal is protected with the di-tert-butylsilyl group44,45 to yield the 
protected glycal 2.11. Installation of the protecting group using the ditriflate reagent provided 
the best results; attempts using the analogous dichloro reagent led to lower yields. It should 
also be noted that other silyl ether protecting groups, such as the tert-butyldiphenyl silyl 
(TBDPS) group, were also examined in the selective protection for the 1º alcohol, but they 
were found to interfere with the subsequent cyclopropanation step. Once the silyl ether 
protecting group was installed, a substrate-directed46 Simmons-Smith cyclopropanation47-49 
was employed to generate compound 2.12. Acetylation of 2.12 was facile and yielded the 
ONA precursor 2.13 in 90% yields. 
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Scheme 2.1 Synthesis of oxepane nucleosides via ring expansion of cyclopropanated glycal 
derivatives.42 Starting from a convenient precursor, 2.9, the oxepine monomer 2.15 can be 
synthesized in six steps. All steps are high yielding, except for the key glycosylation reaction 
that generates 2.14. 
 
 
  From the cyclopropanated glycal derivative 2.13, nucleoside 2.14 can be formed in a 
glycosylation reaction. Because of the generation of a side-product (discussed below in the 
next section), and because of the modest diastereoselectivity, this reaction is low-yielding and 
represents the least efficient step in this synthetic pathway.  Finally, the deprotected 
nucleoside 2.15 can be obtained by treating 2.14 with fluoride (TREAT-HF in THF).  
 
2.2.2 Problems Associated with the Glycosylation Reaction 
 
 The glycosylation reaction shown above in scheme 2.1 is not a simple glycosylation 
reaction. In fact, it involves a Ferrier-type rearrangement50,51 that yields an oxonium 
intermediate43 (shown below in figure 2.5), which then reacts with a nucleophile. Overall, the 
result is a ring-expansion of the glycal derivative 2.13 and the formation of a covalent bond 
with the incoming nucleophile, as can be seen in scheme 2.2.  
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Figure 2.5 TMSOTf catalyzed ring expansion of the cyclopropanated glycal derivative. Once 
the substrate has been activated by TMSOTf, a Ferrier-type rearrangement generates the ring 
expanded oxonium intermediate. 
 
 In Hoberg’s original paper, it was noted that along with the desired ring-expanded 
product, a diene side product 2.16 (shown below in scheme 2.2) was also generated, in 
varying amounts that depended on the nucleophile employed. Thus it was no surprise when 
this side product was also observed in the synthesis discussed in scheme 2.1. When the 
silylated nucleobase was employed as a nucleophile, however, the amount of this diene side 
product was much higher than initially expected. For example, in the original Hoberg paper, 
the amount of the generated diene side product ranged between 0% to 12%;43 in contrast, 
Sabatino and Damha found that the amount of side product observed when a silylated 
nucleobase acts as a nucleophile ranged between 15% to 40%.42  This along with the modest 
diastereoselectivity (10:1 for thymine and only 2:1 for adenosine42) and difficulties 
encountered in the purification account for the overall low yield of this key step. 
 
Scheme 2.2 Glycosylation of cyclopropanated glycal 2.13 generates an α/β mixture of 
diastereomers along with a diene side product 2.16.  
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2.2.3 Initial Work on Improving the Glycosylation Reaction 
 
 Because the key glycosylation reaction shown in scheme 2.1 was low yielding, some 
attempts at improving this step were carried out. The diene side product 2.16 is thought to 
occur through an isomerization mechanism shown in figure 2.6. When a potent nucleophile 
and low temperatures are used, as in the original Hoberg study, the amount of this side 
product is low. However, silylated nucleobases are relatively weak nucleophiles and so the 
original procedure developed by Sabatino and Damha involved refluxing the reaction 
mixture overnight at 81º C. To test whether heat promoted the isomerization, the reaction 
was ran at slightly lower temperatures, but no improvement in the yield of the desired 
nucleoside was noted. 
 
 
Figure 2.6 Proposed mechanisms of diene side product generation and glycosylation 
reaction. The diene 2.16 is generated in an isomerization reaction involving the oxonium 
intermediate (pathway b).  
 
 
Silylation of the nucleobase was carried out in situ with hexamethyldisilazane (HMDS) 
in the original procedure. The in situ silylation of the nucleobase was also carried out with N, 
O-Bis(trimethylsilyl)acetamide (BSA), a typically much more efficient silylating agent, but no 
improvement on the overall glycosylation reaction was observed under these conditions.  
23 
 
2.2.4 Improvement of the Glycosylation Reaction Using Thioglycosides 
 
 As mentioned in previous sections, the glycosylation reaction was actually a Ferrier-
type rearrangement followed by an in situ glycosylation reaction. In an effort to improve 
yields, we separated these two processes into distinct steps. This was achieved by opening the 
ring with trimethylsilylthiophenol (TMSSPh), and then using the resulting thioglycoside, 2.17, 
as a glycosyl donor52-56 in a subsequent glycosylation reaction, shown below in scheme 2.3.  
 
 
Scheme 2.3 Synthesis of ONA via thioglycoside intermediates. Breaking the ring expansion 
and glycosylation reactions into two distinct steps using thioglycosides improves the overall 
yield. Thioglycoside intermediate 2.17 is activated in situ using NBS. 
 
 Ring expansion using TMSSPh as the nucleophile generates a 2:1 diastereomeric 
mixture of anomers, as measured by integration of tert-butyl methyl protons, in 80% yield. In 
the next step, the thioglycoside is activated using N-bromosuccinimide (NBS), a mild 
activation method developed by Hanessian57, and treated with silylated thymine to afford 
ONA 2.14 in 55% overall yield. As in the case of the original synthetic scheme, this approach 
generated a mixture of α/β anomers that were separated by column chromatography. While 
this yield represents an improvement over the original, direct method, the conditions have 
not been optimized and so there exists potential for further improvement. For example, 
experimental parameters such as reaction time, temperature, solvent and in situ activating 
agent for the glycosyl donor could be modified in an effort to improve the reaction sequence. 
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2.3 Initial Work Towards the Dihydroxylated Series 
 
 Under ideal circumstances, the desired dihydroxylated series shown in figure 2.4 
could be synthesized in a three-step process, starting from oxepine 2.15, as shown below in 
scheme 2.4. Because of the inherent difficulty of deoxygenating allylic systems, things are not 
as simple as in this generalized scheme. Attempting to deoxygenate the protected derivative 
of oxepine 2.15 via a Barton deoxygenation58 or even a Myers deoxygenation59 would lead to 
rearrangement of the double bond as both reactions involve radical intermediates (shown in 
figure 2.7).  The net effect of this rearrangement would be the generation of two 
deoxygenated products, which would limit the efficiency and simplicity of the overall process. 
Because of this complication, the actual devised scheme involved additional 
protection/deprotection steps. 
 
 
 
Scheme 2.4 Generalized scheme showing the idealized synthesis of the dihydroxylated series. 
Because of difficulties in deoxygenating allylic systems, actual synthetic scheme is much 
longer, involving protection/deprotection steps. 
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Figure 2.7 Rearrangement of the double bond under radical deoxygenation conditions. In 
either the Myers or Barton deoxygenation, a radical intermediate is generated. This radical 
can either react directly with tributyl tinhydride (not shown), or can react through its 
resonance form. Overall, two deoxygenated products are expected, and the process would 
not be very efficient.  
 
 Since the allylic hydroxyl could not be directly deoxygenated in an efficient manner, a 
synthetic scheme employing the stereodirecting effect of the hydroxyl group was devised, 
and is shown in scheme 2.5.  In outline, synthetic scheme 2.5 was designed to exploit the 
stereodirecting effect of cyclic allylic alcohols. When cyclic allylic alcohols are hydroborated 
with 9-BBN, the main product is typically a 1, 2-anti diol.60 It was hypothesized that the 
combined bulk of the nucleobase and the protecting group at the primary hydroxyl group 
would favor the formation of diastereomers below the ring. In an effort to put the 
stereodirecting effects of the cyclic allylic alcohol and the steric bulk in the same direction, 
the Mitsunobu step was introduced before the hydroboration/oxidation step. In practice, the 
Mitsunobu inversion61-64 step to generate 2.19 proved to be problematic. Initial attempts used 
acetic acid as the acidic component, but led to little conversion. Later experiments used 4-
nitrobenzoic acid, a commonly used acidic pronucleophile in the inversion of secondary 
centers,65 but also failed to generate the desired intermediate 2.19. At this point, the bulk of 
the TBDPS protecting group was suspected to interfere with the Mitsunobu step. Changing 
the 1° protecting group to something less bulky, such as the tert-butyldimethylsilyl (TBDMS) 
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group was considered. But when the total number of steps to get to the desired 
dihydroxylated product was evaluated, a search for a new synthetic scheme began. Starting 
from peracetylated D-glucal, synthesis of the dihydroyxlated targets from figure 2.4 would 
require completing twelve steps. Synthesis of the phosphoramidites, required for 
oligonucleotide synthesis, would necessitate two additional steps, bringing the total to 
fourteen steps. Clearly, a shorter, more efficient synthesis was desirable, and the search for a 
better route was the motivation for the studies carried out in the next chapter.  
 
 
 
 
Scheme 2.5 Initial synthetic scheme for the dihydroxylated targets. The synthetic scheme 
exploits the stereodirecting effect of cyclic allylic systems.  
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2.4 Future Work  
 
2.4.1 Glycosylation Reaction 
 
 Even though the thioglycoside approach was an improvement over the original 
synthesis, more work needs to be done. The overall yield over the ring opening and 
glycosylation steps is 55%, and so this two-step process could be optimized, in an effort to 
increase the overall yield. While this could be achieved by several approaches, a logical 
starting point would involve screening for activator and solvent effects on the yield and 
diastereoselectivity. However, predicting the effects of changing the solvent, activator, or 
even the protecting group on the glycosyl donor on the outcome of a glycosylation reaction 
can be difficult, if not impossible.54,66,67 Thus, it will require some additional experimentation 
to find optimal conditions.  
 Purification of the generated α/β mixture in the synthesis of 2.14 (in both the direct 
and thioglycoside routes) remains a problem. Differing only in one stereocenter, anomers 
have similar physical properties. Their Rf values, in particular, are extremely close to one 
another, complicating routine separation by column chromatography as in the synthesis of 
2.14 (Schemes 2.2 and 2.3). During the purification of these compounds, there is often 
mixing of fractions, which lowers the recovered yield of the desired β anomer. Work towards 
the use of lipases, such as Pseudomonas cepacia lipase, in the purification of α/β mixtures could 
also be carried out. Lipases have been shown to assists in the purification of anomeric 
mixtures of nucleosides by selectively acylating (or hydrolyzing) one anomer over the other, 
allowing for simple subsequent separation.68 Of course, the enzymes may have difficulty 
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recognizing the seven-membered ring, and so this methodology may be difficult to apply to 
oxepane nucleoside derivatives.  
  
2.4.2 Trihydroxylated Monomer Series 
 By modifying scheme 2.5 slightly, a trihydroxylated series of monomer could be 
generated. Direct hydroboration/oxidation of protected 2.23 with 9-BBN should give the 
anti-1,2 diol product 2.24 (as shown in scheme 2.6) as the major product. By inserting a 
Mitsunobu step, the opposite stereochemistry could also be synthesized.  
 
 
  
Scheme 2.6 Direct synthesis of trihydroxylated monomer. Stereoelectronic bias should 
generate the anti-1,2 diol as the major product.  
 
  
 By modifying the hydroborating reagent, the other regioisomer could also be 
synthesized. Evans has shown that hydroboration/oxidation of cyclic allylic systems with 
catecholborane and Wilkinson’s catalyst generates an anti-1,3 diol as the major product. 60,69-71 
This outcome can be exploited to generate the trihydroxylated monomer shown in 
scheme62.7.   
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Scheme 2.7 Direct synthesis of other trihydroxylated monomer. By using Wilkinson’s 
catalyst and catecholborane, the anti-1,3 diol product could be generated . 
 
 
 
 By using schemes 2.6 and 2.7, along with additional Mitsunobu steps, all four 
trihydroxylated monomers, shown below in figure 2.8, could be synthesized. Once the 
trihydroxylated monomers are synthesized and protected, they could be elaborated into 
oligonucleotides, and their biophysical and medicinal properties could be studied. 
 
 
 
Figure 2.8 Trihydroxylated monomer series. These monomers could be synthesized using 
schemes 2.6 and 2.7, and by adding a Mitsunobu inversion step. 
  
   
 
 
 
 
30 
 
Chapter 3 Synthesis of Oxepanes by Ring Closing 
 
3.1 Introduction 
 
 While the ring expansion methodology discussed in the previous chapter was 
effective at synthesizing ONA, it had some drawbacks. The key glycosylation step was tricky 
and low yielding, even after the improvement using thioglycosides as glycosyl donors, and 
would need to be optimized for every desired nucleobase. Synthesis of the initial 
dihydroxylated monomer targets would necessitate multiple transformations, between 12 to 
14 steps, and would likely have to be tuned for each nucleobase. When these difficulties were 
considered, it became clear that new synthetic routes had to be devised and explored. This 
chapter describes the work toward developing new routes in the synthesis of oxepane 
nucleosides. 
 
3.1.1 Synthesis of Oxepane Nucleosides via Ring Closing Metathesis (RCM) 
 
 Early in the search for new synthetic routes, it was reasoned that oxepane 
nucleosides could potentially be synthesized via an RCM reaction, shown below in figure 3.1. 
Ring formation via olefin metathesis72-74 is a powerful and synthetically useful transformation 
in the generation of small, medium and even large macrocyclic ring structures. For example, 
an RCM reaction was employed in the total synthesis of (-)-griseoviridin75, a streptogramin 
antibiotic containing a 23-membered unsatured ring, and in the total synthesis of (+)-
prelaureating,76 a natural product containing an eight-membered ring. Similarly, RCM 
methodology has been employed in nucleic acid chemistry, and in particular by Poul Nielsen 
in the synthesis of novel nucleotides containing bridged structures between the sugar moiety 
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and the phosphate backbone.77-79 Based on literature precedents, a simple RCM reaction 
generating an oxepane monomer 3.1 from an acyclic diene seemed like a potentially effective 
route to oxepane nucleosides. The diene precursor 3.2 could in principle be synthesized by 
synthetic transformations of the open-chain nucleosides, alternatively called 
seconucleosides80-83 or unlocked nucleic acids.84 Seconucleosides in turn can be synthesized 
from the corresponding ribonucleoside via sodium periodate cleavage followed by in situ 
reduction with sodium borohydride.85,86 
  
 
 
Figure 3.1 Key retrosynthetic disconnect in the proposed synthesis of oxepane nucleosides 
via an RCM approach. 
  
 
 
 Since the precursor 3.2 could be synthesized from a seconucleoside derivative, this 
synthetic approach would circumvent the glycosylation reaction and all the associated 
difficulties. Once an oxepane ring structure, such as in 3.1, would be synthesized, it could be 
derivatized to generate modified ONA monomers. Because this approach started from 
commercially-available ribonucleosides, and because it had the potential to be a much 
quicker synthesis than the original ring expansion synthesis, this approach was pursued by 
several different synthetic routes.  
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3.2 Wittig Chemistry Synthetic Route 
 
 An initial approach towards synthesizing the RCM-derived ONA monomer 3.8 was a 
one-carbon homologation sequence employing the Wittig olefination87 as the main carbon-
carbon bond forming reaction (shown below in scheme 3.1). 
 
Scheme 3.1 Wittig-based approach to synthesizing ONA monomer 3.8. Strategy involves 
sequential one carbon homologation reactions using Wittig chemistry.                                      
 
 This approach allows for the use of commercially available nucleosides, uridine 3.3 in 
this case, as a starting material, thus obviating the need for a glycosylation reaction as in the 
previous synthetic routes. For protection of the 5' OH group, the monomethoxytrityl group 
(MMTr) was chosen because of its stability, and also for its compatibility with solid-phase 
chemistry. Once the protected nucleoside 3.4 was synthesized the subsequent synthetic 
strategy involved a carbon-carbon bond step formation via the Wittig reaction, generating 
dialkene nucleoside88,89 3.5, and finally a hydroboration-oxidation to generate 3.6. Once the 
homologated seconucleoside 3.6 was generated, the idea was to oxidize the diol via a Swern 
oxidation, and to extend the carbon chain by one more unit on each side with a Wittig step, 
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generating the RCM precursor 3.7. However, as discussed below, difficulties were 
encountered in the generation of 3.5 and 3.6.   
 
3.2.1 Solution Structure of Nucleoside Dialdehydes 
  
 Initial attempts to synthesize dialkene nucleoside derivative 3.5 were surprisingly 
difficult. Starting from the protected nucleoside 3.4, it involved the formation of an 
intermediate nucleoside dialdehyde, followed by a one-carbon extension using a methylene 
phosphorane reagent. Generation of the dialdehyde involved sodium periodate cleavage, and 
then subsequent use of the product without purification. But in all cases, attempts at Wittig 
methylenation failed. Examination of the 1H NMR spectrum of the intermediate dialdehyde 
led to the surprising realization that the nucleoside dialdehyde was not one compound, but 
was actually a mixture of compounds having identical Rf values on TLC. Examination of 
older literature on nucleoside dialdehydes revealed that in solution uridine “dialdehydes” are 
actually a series of hydrated dioxane nucleosides, shown below in figure 3.2, in equilibrium 
with a very small amount of actual dialdehyde.90 
 
 
 
Figure 3.2 Solution structure of uridine “dialdehydes.” Upon oxidative cleavage of uridine, 
the dialdehyde forms stable hydrated dioxane nucleosides, shown here in the chair 
conformation. Although there are four possible diastereomers, only the three shown are 
expected to be favored. Having the two hydroxyl groups axial incurs a high energetic penalty, 
and so this may explain why a fourth diastereomer is not observed.  
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3.2.2 Dehydration of Dioxane Nucleosides 
 
 After learning that treating nucleosides with sodium periodate led to the formation of 
stable, isolable dioxane nucleosides, it was decided that dehydration of the cyclic acetal 
structures to the dialdehyde needed to be explored. The dehydration reaction should 
essentially be the reverse of the initial hydration of the actual dialdehyde and is shown in 
figure 3.3. 
 
 
Figure 3.3 Dehydration of dioxane nucleosides and hydration of the dialdehyde (reverse 
reaction).  
 
 
 To effect this dehydration, the dioxane nucleoside mixture was dissolved in benzene 
and refluxed. With the aid of a Dean-Stark trap, the water was removed over a 2 hour period, 
and then the solvent condensed down under reduced pressure. Several subsequent 
azeotropic condensations from benzene were carried out, and the resulting spectra (shown in 
figures 3.4 and 3.5) were contrasted. Later trials simply employing azeotropic condensations 
from benzene were used, though the extent of dehydration seemed less. In either case, 
however, the dehydrated nucleosides were more reactive in the next reaction step, the Wittig 
methylenation, which will be discussed in the following section.  
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Figure 3.4 1H spectrum of the dioxane nucleoside mixture. In the 5.0-6.0 δ range a 
multiplicity of signals can be seen. In the aldehyde regions, shown in the inset, no sharp 
signals are observed.  
 
 
 
Figure 3.5 1H spectrum of the dehydrated nucleoside. In the 5.0-6.0 δ range, only two main 
signals can be seen, corresponding to the anomeric and H5 (nucleobase) protons. In the 
aldehyde region, shown in the inset, two sharp signals are clearly visible.  
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 As can be seen in the above spectra, there are striking differences between the 
resulting compounds. In the case of the dioxane nucleoside diastereomers, there is a 
multiplicity of signals in the 5.0-6.0 δ range, but there is only a broad singlet in the aldehyde 
region, likely being the N3 imido proton of the nucleobase. In stark contrast, the dehydrated 
nucleoside only has two signals in the 5.0-6.0 δ, corresponding to the anomeric and H5 
(nucleobase) protons, though there are some weaker signals buried under the H5 region. 
Conspicuously and importantly, however, there are two sharp aldehyde signals in the 9.6 to 
9.9 δ range, indicating that the dioxane ring had effectively been dehydrated.  
 
3.2.3 Synthesis of Dialkene Nucleoside 
 
  
With the dioxane ring dehydrated to the corresponding dialdehyde, the Wittig 
reaction was repeated. Initial attempts using butyl lithium as the base led to long reaction 
times and little conversion to the desired dialkene nucleoside. However, switching the base 
to potassium tert-butoxide (KOtBu) resulted in much quicker reaction times. As had been 
previously noted in the literature, there seems to be a lithium salt effect that slows the 
decomposition of the oxaphosphetane intermediate into the alkene and triphenylphosphine 
oxide.91 Yet even when using KOtBu as the base, the yields were low, around 27%, and a 
non-polar side product, later identified to be tritanol, was observed. Since the MMTr 
protecting group is stable to basic conditions, this detritylation was unexpected and puzzling. 
However, consideration of the intermediate dialdehyde and the potential for enolization has 
led to a proposed mechanism, which will be discussed below in the next section.  
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3.2.4 Proposed Mechanism of Detritylation 
 
 
 
Figure 3.6 Proposed mechanism of detritylation. Since the α protons of the dialdehyde 
nucleoside, shown in red, are relatively acidic, the aldehyde has the potential to enolize. 
Enolization could be followed by E1cB elimination. 
  
 Because it was unusual to observed detritylation under basic conditions, some 
thought was put into proposing a plausible mechanism. For this discussion, aqueous pKa 
values are used, though the actual magnitudes in organic solvents are of course different. 
Formation of the ylide employs KOtBu as the base, and so the pKa of the phosphonium salt 
must be lower than 18, likely in the 15 to 16 range for quantitative formation of the ylide to 
occur. In the dialdehyde nucleoside, the pKa values of the two protons alpha to the 
aldehydes, shown in red, must be below 17, as the pKa values of an α proton in an alkyl 
aldehyde is near 17. Because of the inductive effects of the adjacent heteroatoms, the pKa 
values of both α proton in the dialdehyde nucleoside must be below 17, possibly 16 or so. 
From this analysis, it seems plausible that the aldehydes have the potential to enolize under 
these conditions. Once the enol forms, it may have the potential to undergo an E1cB type 
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elimination, forming an α/β unsaturated system and eliminating the MMTr protecting group 
as a tritanol derivative.  
 
3.2.5 Hydroboration-Oxidation of Dialkene Nucleosides 
 
 Once the dialkene nucleoside 3.5 was synthesized a hydroboration-oxidation reaction 
was carried out, and is shown below in scheme 3.2.  
 
 
Scheme 3.2 Hydroboration-oxidation of dialkene nucleoside using 9-BBN. Reaction 
generated a mixture of diols.  
 
 For the hydroboration step, 9-BBN, a commercially-available reagent was used. For 
the oxidation step, sodium perborate, in lieu of the classical alkaline hydrogen peroxide 
system, was used. In comparative studies, sodium perborate has been found to be at least as 
good (and often better) than hydrogen peroxide-based oxidation.92 Using these conditions, a 
mixture of diols, as evidenced by five spots on TLC, was observed after workup. 
Hydroborations of simple terminal alkenes typically give the terminal alcohol when 9-BBN 
and standard times and conditions are used.93 But in this system there are also electronic 
factors, as well as the simpler steric effects to consider. Even though 9-BBN is often highly 
regioselective for the formation of terminal organoboranes,94 it is also sensitive to electronic 
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factors from neighboring functional groups, such as electron-withdrawing alkoxy groups.95 
To see if another hydroborating reagent could lead to better selectivity, dicyclohexylborane, 
Chx2BH, was assayed. Because Chx2BH is not commercially available from commonly used 
chemical suppliers, it was made in situ and used immediately, as shown below in scheme 3.3.  
 
 
Scheme 3.3 Hydroboration-oxidation using dicyclohexylborane, Chx2BH. The 
hydroborating reagent was made in situ then used. Hydroboration-oxidation led to a mixture 
of diol products.  
 
 Similar to the reactions carried out with 9-BBN, hydroboration-oxidation with 
Chx2BH lead to a mixture of products. At this point, hydroborations with other reagents, 
such as disiamylborane, were considered, as well as changing reaction conditions, such as 
temperature and hydroboration time. But when the low yield of the previous Wittig step was 
considered, along with the sheer number of possible isomers potentially generated in the 
hydroboration-oxidation reaction, shown below in figure 3.7, it was decided that new 
synthetic routes should be examined.  
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Figure 3.7 All possible isomers potentially generated in the hydroboration-oxidation 
reaction. Because of the electronic effects of the alkoxy groups and of the nucleobase, and 
because the transformation involves two alkenes, there are nine possible isomers, a factor 
greatly complicating a seemingly simple reaction.  
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3.3 Grignard Chemistry Synthetic Route 
 
 Because of the difficulties encountered in the Wittig chemistry scheme, a new 
approach based on the addition of an organometallic reagent, vinylmagnesium bromide,96 
was devised. Addition reactions of Grignard reagents97 to mesylates and alkyl iodides had 
been seen in the literature,98 and it was felt that if this synthetic scheme were successful, it 
would be much more elegant and streamlined than the previous approach. Instead of adding 
carbons one at a time, in a stepwise manner, the two carbons needed for the RCM precursor, 
3.7 in scheme 3.4, could be added in one step, dispensing with the need for additional steps 
to adjust the oxidation state.  
 
Scheme 3.4 Grignard chemistry synthetic scheme. The approach involves the addition of 
two carbon units in one reaction step.  
 
 
 
 
 
42 
 
3.3.1 Synthesis of Dimesylate 
 
 Starting from protected ribouridine, 3.4 the dimesylate 3.10 can be synthesized in two 
steps, as seen below in scheme 3.5. To synthesize seconucleoside 3.9, oxidative cleavage with 
sodium periodate, followed by in situ reduction with sodium borohydride86 is carried out and 
affords the desired acyclic nucleoside in near quantitative yields. Opening of the ribose ring 
produces a characteristic spectral signature of triplet resonances, as seen below in figure 3.8.  
In deuterated DMSO, the anomeric proton as well as the 2' OH and 3' OH appear as sharp, 
distinct triplets. Once seconucleoside 3.9 is worked up, it can be used in the next step 
without further purification. Formation of the dimesylate 3.10 is carried out by treating the 
nucleoside in pyridine with mesyl chloride,99 and is fairly high yielding, with yields in the 80% 
range.   
 
 
 
Scheme 3.5 Synthesis of dimesylate 3.10 from protected uridine. Oxidative cleavage 
followed by reduction forms the seconucleoside 3.9, which then reacts with mesyl chloride in 
pyridine to form the dimesylate 3.10.   
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Figure 3.8 Expansion of 1H NMR (DMSO-d6) of seconucleoside 3.9. Opening of the ribose 
ring generates a pattern of triplets. The anomeric proton, H1', appears as a downfield triplet. 
In between the sugar protons, the H5 signal of the nucleobase appears as a sharply resolved 
doublet. Finally, the two hydroxyl protons appear as sharp triplets.  
 
3.3.2 Vinylation Reaction with Vinylmagnesium Bromide  
 
 With the dimesylate 3.10 synthesized, attention was turned to attempting a coupling 
using vinylmagnesium bromide, and is shown below in scheme 3.6. Initial attempts were 
carried out at 0 ºC, but no reaction was observed. Only starting material was recovered. 
 
 
Scheme 3.6 Vinylation reaction with vinylmagnesium bromide. Trials at low temperatures 
lead to no reactions; trials at ambient temperature led to an inseparable mixture of products.  
 
 
H1' H5 2' OH 3' OH 
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Raising the temperature to ambient temperature in the presence of additives, such as 
catalytic CuI or TBAI, however, led to observed reactions. But in this case, the substrate was 
too reactive, and multiple spots were observed on TLC. Purification by column 
chromatography revealed that within the most non-polar spot, there were multiple, 
inseparable compounds, as evidenced by the multiplicity of signals observed in the H6 
(nucleobase) and anomeric regions, shown below in figure 3.9. In a pure seconucleoside, the 
anomeric proton, H1', should appear as a triplet, and the H6 nucleobase proton should 
appear as a doublet. Estimating from these 1H NMR regions, there appeared to be at least 
four inseparable compounds in this one spot on TLC. Clearly, a more chemoselective 
approach was needed, and so our attention turned to stoichiometric organocopper chemistry.   
 
 
 
 
Figure 3.9 Expansions of the H6 and anomeric regions of the mixture isolated from the 
conversion of 3.10 to 3.7 (scheme 3.10).  As seen in the multiplicity of signals in both these 
regions, the reaction generated a mixture of inseparable products.  
 
 
 
 
H6 Region Anomeric Region 
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3.4 Organocopper Chemistry Synthetic Route 
 
 
 Because of the chemoselectivity problems observed with Grignard reagents, it was 
necessary to change the nucleophilic component in the coupling step in scheme 3.4. Since it 
was desirable to maintain a stepwise and streamlined approach, a vinyl-based organocopper 
species was required. Organocopper reagents, such as Gilman reagents, are well-established 
in the literature and are typically more effective at coupling with saturated electrophiles than 
Grignard reagents.100-103 However, organocopper chemistry can be challenging technically. In 
practice, a myriad of factors affect the stability and reactivity of cuprate regents, including 
nature and purity of the copper (I) salt; presence and concentration of halide salts; 
temperature; oxygen content of the solvents; composition of solvent systems; and additives 
such as ligands and HMPA.  
3.4.1 Synthesis of Ditosylate Nucleoside 
 
When the initial organocopper coupling experiments were designed, copper iodide, 
the most common copper (I) salt, was chosen. Reports in the literature indicated that 
tosylates104,105 were the best leaving groups for reactions with Gilman reagents, and so a 
ditosylate seconucleoside was selected as the substrate. Initial attempts at forming a ditosylate 
nucleoside were meet with some difficulties; and an examination of the literature indicated 
that the N3 imido function needed to be protected.80 While many protecting groups106-108 
were available to protect the nucleobase’s N3 imido nitrogen, the p-methoxybenzyl group 
(PMB) was chosen. The PMB protecting group can be installed selectively on the N3 imido 
nitrogen, even in the presence of free hydroxyl groups, and can be removed under relatively 
mild conditions.109 Outside of nucleoside chemistry, the PMB group has also been employed 
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in the context of a total synthesis of  tunicamycins110 by Danishefsky, illustrating the wide 
applicability of this protecting group.  
Shown below in scheme 3.7 is the synthesis of protected ditosylate nucleoside 3.12. 
Starting from protected ribouridine 3.9, the desired ditosylate 3.12 was synthesized in two 
steps. Selective protection of N3 imido nitrogen with the PMB group was facile, even in the 
presence of the two primary hydroxyl groups. Subsequent ditosylation81,111 required longer 
reaction times than dimesylation, but yielded the desired substrate in good yields 
 
 
Scheme 3.7 Synthesis of ditosylate nucleoside from protected ribouridine.  
 
Installation of the PMB group produces a classical AB quartet in the 1H NMR 
spectrum, and is shown in figure 3.10. This signal is associated with the diastereotopic 
methylene hydrogens. 
Figure 3.10 Expansion of 1H NMR (DMSO-d6) of seconucleoside 3.11. Installation of the 
PMB group produces a characteristic AB quartet, due to the PMB’s group methylene protons. 
 
H1' H5 2'OH 3' OH PMB –CH2- 
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3.4.2 Vinylation Reaction with Lithium Divinyl Cuprate 
 
 Once the ditosylate substrate 3.12 was synthesized, the coupling reaction was 
attempted (shown below in scheme 3.8) using lithium divinyl cuprate, a Gilman reagent. 
When the reaction was carried out at -40 °C, no reaction was observed. When the reaction 
was allowed to warm to 0 °C, color changes were observed, indicating that the Gilman 
reagent was decomposing, and unreacted starting material was recovered.  
 
 
 
Scheme 3.8 Vinylation reaction with lithium divinylcuprate. Trials at -40 °C to 0°C did not 
produce the desired divinyl seconucleoside.   
 
                                                                    
 
Instead of immediately abandoning this route, some attempts were made to 
troubleshoot this reaction.  Since the lithium divinyl cuprate Gilman reagent was made in situ, 
as shown below in figure 3.11, the concentration of t-BuLi solution needed to be determined 
by titration. Many indicators for organolithium titrations112-115 are available, but 1,3-diphenyl-
2-propanone tosylhydrazone was selected as the preferred indicator because of its sharp and 
easily observable endpoint.116  
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Figure 3.11 Formation of lithium divinyl cuprate. The Gilman reagent was formed in situ by 
a two-step process. First, vinyl bromide was converted to vinyl lithium via a lithium-halogen 
exchange reaction; then the Gilman reagent was formed by reacting the organolithium with 
copper iodide. 
 
Once the quality of the t-BuLi had been ascertained, the copper iodide was purified 
by an existing protocol; purity of the copper salt is often critical to the success of coupling 
reactions.117 Finally, the Gilman test,118 using Michler’s ketone was carried out, and is shown 
in figure 3.12. This qualitative test, first devised by Henry Gilman, allows for the detection of 
organolithium species. Since Michler’s ketone does not react with organocopper reagents, the 
Gilman test allows for the indirect monitoring of Gilman reagent formation. Though useful, 
the Gilman test, it must be noted, cannot detect decomposition of the newly-formed Gilman 
reagents and so has limitations. 
 
  
Figure 3.12 Gilman test for the presence of organolithium reagents. Treating an 
organolithium reagent with Michler’s ketone produces a color change. Organocopper 
reagents do not produce a color change. 
 
  
 
 Even after taking these additional steps, attempts at nucleophilic coupling with 
lithium divinyl cuprate still did not yield the desired RCM precursor 3.13. Accounts in the 
literature indicated that vinylic cuprates tend to be unstable and prone to thermal and 
oxidative decomposition119,120. Moreover, vinylic cuprates tend to be less reactive than alkyl – 
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or even aryl – cuprates, further complicating the chemistry of this crucial step.103 At this 
point, it seemed like the organocopper route was a synthetic dead-end, but before 
abandoning it, a few more alternatives were explored.  These are discussed in the following 
section. 
3.4.3 Alternative Organocopper Approaches 
 
 To see if changing the leaving group would have an effect, the ditosylate 3.12 was 
converted to the di-iodo derivative 3.15 via the Finkelstein reaction,121 and is shown below in 
scheme 3.9. Formation of the di-iodo required reflux conditions, as the Finkelstein reaction 
often does, but yielded the desired nucleoside in 92% yield. However, subjecting the di-iodo 
nucleoside to the same nucleophilic coupling conditions did not led to any observable 
product formation.  
 
Scheme 3.9 Vinylation reaction attempt with di-iodo nucleoside. Di-iodo nucleoside 3.15 
was formed via the Finkelstein reaction. 
 
To enhance the stability of the Gilman reagent, phosphine ligands100,122 were also 
assayed, but were not found to have an effect on the coupling reaction. Alternative copper 
salts, such as copper bromide102,123 and copper cyanide124,125 were also examined, but did not 
help this critical step. Other additives and conditions could have been assayed, but it was felt 
that the organocopper route was indeed a synthetic dead-end and that other approaches 
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should be developed. It was surmised that the lithium divinyl cuprate reagent was too 
sluggish and unstable to effectively undergo the coupling reaction. However, formation of 
the di-iodo nucleoside 3.15, via the Finkelstein reaction, illustrated that nucleophilic coupling 
was indeed possible with a seconucleoside substrate.  
3.5 Nitrile Chemistry Approach 
   
Because of the difficulties encountered in the Grignard and organocopper routes, it 
was necessary to devise another approach. Formation of the di-iodo nucleoside 3.15 
demonstrated that simple nucleophilic coupling could be used to generate seconucleoside 
derivatives. Building on this fact, a new synthetic scheme involving nitrile chemistry was 
formulated, and is shown below in scheme 3.10. 
 
 
Scheme 3.10 Nitrile chemistry synthetic route. Formation of desired RCM precursor 3.13 is 
planned by adding one-carbon units at a time, and involves nitrile and Wittig chemistry. 
 
 
 In this approach, a dihalide, like dichloro 3.16, is formed via a direct halogenation 
reaction from the doubly-protected seconucleoside 3.11. Nucleophilic displacement with 
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cyanide would extent the carbon framework by one unit, generating dinitrile 3.17. From this 
intermediate, a reduction with DIBAL would generate a homologated dialdehyde, which 
when subjected to a Wittig methyleneation could generate the desired RCM precursor 3.13. 
Since the dialdehyde intermediate 3.18 contained extra carbons, it was surmised that the 
earlier problems of cyclization (section 3.2.1) and multiple hydroborations (section 3.2.5) 
would not be as significant, and so this could be a viable route. However, when this synthetic 
route was explored, problems were encountered in the formation of the dinitrile intermediate, 
and are discussed below.  
3.5.1 Acetonitrile-Crown Ether System for Nitrile Route 
 
 Nucleophilic substitution of halides by cyanide can be accomplished under various 
conditions, and as a starting point an acetonitrile-crown ether system was assayed. These 
conditions have been reported to be more efficient than ethanol-water solvent systems, and  
have been shown to work well even with bromides and chlorides in simple model systems, 
such as 1-chlorohexane and 1-bromohexane.126 Synthesis of the dichloronucleoside 3.16, 
shown below in scheme 3.11, proceeded smoothly, and in good yields, via a direct 
halogenation reaction employing triphenylphosphine and carbon tetrachloride in DCM.127 
However, treating this chlorinated substrate with KCN and the 18-C-6-MeCN system did 
not lead to any reaction, even with extended reaction times and even under reflux conditions. 
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Scheme 3.11 Nitrile synthetic route with dichlorides. Synthesis of dichloronucleoside 3.16 
was accomplished via a direct halogenation reaction. The resulting dichloronucleoside was 
unreactive in the subsequent step. 
 
Since the dichloronucleoside 3.16 proved to be too unreactive, a dibromonucleoside, 
3.19 shown below in scheme 3.12, was synthesized. Formation of the brominated nucleoside 
was accomplished via a direct bromination reaction.128-130 However, subjecting this more 
reactive substrate to the same 18-C-6-MeCN system did not lead to any observable reaction; 
only starting material was recovered.  
 
 
Scheme 3.12 Nitrile approach route with dibromides. Synthesis of dibromonucleoside 3.19 
was accomplished via a direct halogenation reaction. The resulting brominated nucleoside 
was unreactive in the subsequent step. 
 
3.5.2 DMSO and DMF Solvent Systems for Nitrile Route 
 
 Because of the lack of reactivity observed in the previous system, alternative 
conditions needed to be found. Examination of the literature showed many cases where 
halides were displaced by cyanide in DMSO or  DMF, even in the absence of crown 
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ethers.131-133 To test these conditions, di-iodonucleoside 3.15 was synthesized via a direct 
iodination134,135 reaction and used as the substrate. When this substrate was reacted with 
NaCN in DMSO at 40°C, the main recovered product was PMB-protected uracil, 3.20, and 
is shown below in scheme 3.13. At room temperature, no reaction was observed. DMSO is 
known to be a reactive, nucleophilic solvent,136 and so to rule out the possibility of a solvent 
effect, the reaction was repeated with DMF as the solvent, at 80 °C, and with KCN as the 
cyanide source. However, when the reaction was repeated under these conditions, the 
protected nucleobase, 3.20, was again the main recovered product (at room temperature, no 
reaction was observed.). The exact mechanism for the decomposition of the nucleoside is 
not known, but may involve a substitution of the 2' iodine, followed by an elimination 
reaction. Direct nucleophilic substitution of the protected nucleobase by cyanide seems like 
an implausible reaction pathway, though it is of course possible. Regardless of the 
mechanism involved, these results indicated that a new synthetic route needed to be found. 
  
 
 
Scheme 3.13 Nitrile approach route with iodides.. When this iodinated nucleoside was 
reacted with cyanide in DMSO or DMF, displacement of the protected nucleobase, 3.20, was 
observed. 
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3.6 Negishi Coupling Approach 
 
 
 Up till this point, all of the synthetic approaches studied relied on nucleophilic cross-
coupling, so the logical next step was to attempt a metal-catalyzed cross coupling reaction. 
The Negishi reaction, in particular, is a palladium (or nickel) catalyzed cross-coupling 
reaction that allows for carbon-carbon bond formation between saturated and unsaturated 
components.137,138 In this approach, di-iodo nucleoside 3.15 was transformed into a 
diorganozinc halide in situ, and then reacted with vinyl bromide in the presence of palladium 
(0). When this reaction was initially carried out, it looked promising because complete 
consumption of starting material, as monitored by TLC, was observed within 3.5 hours. 
Inspection of 1H NMR of the product indicated that coupling had indeed occurred, as 
evidenced by the appearance of signals in the olefinic region of the spectrum. However, this 
occurred with concomitant loss of the nucleobase through some unknown reaction pathway. 
Since the reaction conditions had been modeled on previous reports on the coupling of a 
homoallylic iodide, a fairly labile substrate, with a vinyl iodide fragment, this result was 
surprising.139 Repeating this reaction, however, led to the same outcome and so this approach 
was abandoned.  
 
 
Scheme 3.14 Negishi coupling approach using iodinated seconucleoside. Reaction led to 
some coupling with concomitant loss of the nucleobase.  
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3.7 Addition of Grignard Reagents to Dialdehyde Nucleosides 
 
  
  Even though synthetic roadblocks had been encountered in the previous attempts, 
the search for a synthetic method that would enable us to synthesize ONA monomers via an 
RCM approach was pursued.  Few new methods, it seemed, were left to try, but the direct 
addition of a Grignard reagent to a nucleoside dialdehyde substrate was still unexplored. 
While designing this experiment, it was decided to leave the nucleoside unprotected at the 
N3 position to limit the amount of potential elimination product. In the presence of strong 
bases, such as Grignard regents, the N3 imido proton becomes deprotonated, generating an 
anion. For a subsequent elimination to occur, the nucleobase would have to leave as a 
dianion, which would be energetically unfavourable. To test this approach, a dialdehyde was 
generated in situ by the methods discussed in section 3.2. Subjecting this unstable 
intermediate to a Grignard addition with vinylmagnesium bromide, followed by a Grubbs II 
mediated RCM led to an inseparable mixture of ONA diastereomers, 3.21, as shown in figure 
3.15. Mass spectral analysis of the mixture showed peaks in the negative mode corresponding 
to the expected molecular weight. HRMS confirmed the elemental composition of 3.21 as 
being C31H29N2O7 (for M-H
+ in the negative mode).  
 
 
Scheme 3.15 Direct addition of vinylmagnesium bromide to an intermediate dialdehyde 
followed by RCM with Grubbs II led to an inseperable diastereomeric mixture 3.21. 
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 ONA mixture 3.21 was subsequently subjected to acetylation with acetic acid and 
pyridine, in an effort to alter the Rf values of the diastereomers and allow for 
chromatographic separation. However, the resulting diacetylated ONA mixture proved to be 
inseparable. HRMS analysis of the product of this reaction confirmed the molecular weight 
and elemental composition of the diacetylated ONA derivative.  
3.8 Future Work 
 
While the previous approach was a proof-of-principle for the synthesis of ONA via a 
ring-closing metathesis approach, it generated an inseparable mixture of diastereomers and 
introduced an unstable dialdehyde intermediate, factors which greatly limit the synthetic 
utility of this scheme.  In order to fully explore this new approach to synthesizing ONA, a 
new scheme, shown below, is proposed. 
 
Scheme 3.16 Proposed scheme for the synthesis of ONA via a ring closing approach.   
57 
 
 
To avoid the formation of the dialdehyde and to avoid the diastereoselectivity 
problem, a stepwise approach is suggested where only one stereocenter is set at a time. Since 
this synthesis would start with seconucleoside 3.9, the intermediate dialdehyde would be 
avoided altogether. Monoprotection86 of 3.9 with TBSCl, followed by separation of the 
monoprotected products would generate compound 3.22. The subsequent steps involve 
performing Grignard additions sequentially.  Key to this approach is the judicious use of the 
metal to tune the Felkin-Ahn or Cram Chelate selectivity in the Grignard addition steps used 
to generate intermediates 3.24 and 3.27. Metals components, labeled M in scheme 3.16, 
ranging from Ti(OiPr)3, TiCl3, Zr(OiPr)3, to AlMe3, could be assayed to maximize the 
stereoselectivity of the Grignard addition reaction.140 To limit the protection/deprotection 
steps, a selective oxidation (employing TEMPO/NaOCl as the oxidant) of the primary 
alcohol over the secondary alcohol is proposed to generate structure 3.26.141 Once the RCM 
precursor 3.27 is synthesized, the desired oxepene monomer could be made via a ring closing 
metathesis. By tuning the stereoselectivity of the Grignard addition steps, four different 
diastereomers could in principle be generate by this method.  
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Chapter 4 Experimental 
 
4.1 General Methods 
 
4.1.1 Solvents and Reagents 
Anhydrous tetrahydofuran, dicholoromethane and acetonitrile were dried using an 
Mbraun solvent purification system. Anhydrous DMF and DMSO were obtained from 
sequential drying over molecular sieves. Anhydrous benzene was obtained by drying over 
activated alumina, Brockmann activity I. Pyridine was dried by distillation over CaH2. 
Acetone was dried by stirring over 3 Å molecular sieves for 4 hours or by alternatively by 
stirring over boric anhydride followed by distillation. Sodium iodide was dried by heating 
(with stirring) in vacuo overnight in the dark. Methyltriphenylphosphonium bromide, 
MMTrCl, nucleosides and other reagents were dried by azeotropic condensations from 
benzene, toluene or pyridine. Molecular sieves were activated by heating under reduced 
pressure to drive off water. Other anhydrous solvents and reagents were purchased from 
Sigma-Aldrich. All anhydrous reactions were carried under an atmosphere of nitrogen gas in 
flame-dried glassware. 
4.1.2 Purification and Characterization of Compounds 
 Compounds were purified column chromatography using 40-60 micron (230-400 
mesh) silica gel from Silicycle. Reactions were monitored by thin-layer chromatography using 
Merck Kieselgel 60 F-254 aluminum backed silica gel sheets. Visualization was achieved 
using UV light and with 5 % solutions of H2SO4 in MeOH. NMR spectra were obtained 
using 500 MHz, 400 MHz and 300 MHz instruments. Solvent peaks of CDCl3 and DMSO-
d6 were used as internal standards. Routine mass spectral data was acquired using low 
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resolution ESI-MS in both negative and positive modes. Elemental composition of certain 
compounds was obtained using HRMS analysis.  
4.2 Chapter 2 Characterization 
 
 
D-Glucal (2.10) 
 
 
 
 
 To a stirred solution of peracetylated D-glucal 2.9 (5.023g, 18.47 mmol) in 40 mL of 
MeOH was added 0.050 mL of 25% NaOMe/MeOH. After 2.5 hours at room temperature, 
the solvent was removed by rotary evaporation. Subjecting the crude mixture to column 
chromatography (9:1 DCM/MeOH) yielded 2.668 g of 2.10 as a white solid. 1H NMR (400 
MHz, D2O) δ 6.45 (d, J = 6.1, 1H), 4.84 (dd, J = 6.1, 2.4, 1H), 4.26 (d, J = 7.0, 1H), 3.98 – 
3.86 (m, 3H), 3.75 – 3.64 (m, 1H). ESI-MS calcd. for C14H26O4Si [M+Na
+] 309.16, found 
309.17.  
4,6-O-Di-(tert-butyl)silanediyl-D-glucal (2.11) 
 
Dissolved 2.10 (2.612 g, 17.89 mmol, 1eq) in 70 mL of anhydrous DMF under 
constant N2 flow. The resulting solution was then cooled to -40 °C. Added t-Bu2Si(OTf)2 
dropwise (6.93 mL, 21.44 mmol, 1.2 eq) over a period of five minutes. Reaction was then 
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stirred at -40 °C for 50 minutes. Quenching of the reaction was achieved by adding 2 mL of 
pyridine (24.73 mmol, 1.4 eq) followed by stirring for an additional 15 minutes. Diluted 
reaction mixture with ethyl acetate; and organic layer was washed successively with 5% 
NaHCO3 and brine solutions, dried with MgSO4 and concentrated in vacuo. Purification of the 
crude product by column chromatography (25:1 to 5:1 gradient Hexanes/EtOAc) afforded 
4.090 g of 2.11 as a white solid. 1H NMR (400 MHz, CDCl3) δ 6.25 (dd, J = 6.0, 1.8, 1H), 
4.74 (dd, J = 6.1, 1.9, 1H), 4.28 (d, J = 6.0, 1H), 4.16 (dd, J = 10.2, 4.9, 1H), 3.98 – 3.77 (m, 
3H), 2.39 (d, J = 2.0, 1H), 1.05 (s, 9H), 0.97 (s, 9H). ESI-MS calcd. for C14H26O4Si [M+Na
+] 
309.16, found 309.17.  
1,5-Anhydro-2-deoxy-1,2-C-methylene-4,6-O-(di-tertbutylsilanediyl)-D-glycero-D-
hexitol (2.12) 
 
 To a stirred solution of 2.11 (1.323 g, 4.62 mmol) in 20 mL of anhydrous diethyl 
ether at 0 °C was added 12.60 mL of 1.1 M diethyl zinc solution (13.86 mmol, 3 eq) drop 
wise followed by 1.12 mL of CH2I2 (13.86 mmol, 3 eq) under flow of N2. When the reaction 
had gone to completion after 6 hour, 50 mL of saturated NH4Cl solution was added as a 
quenching agent. The aqueous layer was extracted with ethyl acetate; and the organic extracts 
were washed with 5% NaHCO3 and saturated brine solutions. Drying of the organic layer 
was effected by MgSO4, and the solvent was removed by rotary evaporation. Subjecting the 
crude reaction mixture to flash column chromatography (10:1 to 5:1 gradient 
hexanes/EtOAc) afforded 1.219 g of 2.12, which was collected as a white solid. 1H NMR 
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(400 MHz, CDCl3) δ 4.15 (t, J = 7.4, 1H), 4.07 (dd, J = 10.4, 4.9, 1H), 3.78 – 3.73 (m, 1H), 
3.68 (t, J = 10.2, 1H), 3.48 (dd, J = 9.7, 8.0, 1H), 3.36 (td, J = 10.0, 5.0, 1H), 2.55 (bs, 1H), 
1.48 – 1.39 (m, 1H), 1.03 (s, 9H), 0.97 (s, 9H), 0.79 – 0.71 (m, 2H). ESI-MS calcd. for 
C15H28O4Si [M+Na
+] 323.18, found 323.20.  
3-Acetyl-1,5-anhydro-2-deoxy-1,2-C-methylene-4,6-O-(di-tert-butylsilanediyl)-D-
glycero-D-hexitol (2.13) 
 
 To a stirred solution of 2.12 (2.592 g, 7.57 mmol, 1 eq) and a catalytic amount of 
DMAP (90 mg) in 15 mL of anhydrous pyridine was added 3.258 mL of Ac2O (34.47 mmol, 
4.5 eq) dropwise at 0 °C and under an atmosphere of N2. When the reaction had gone to 
completion, as monitored by TLC, the reaction mixture was diluted with diethyl ether. The 
organic layer was washed with water, dried with MgSO4, and concentrated in vacuo. 
Purification by column chromatography (10:1 to 5:1 hexanes/EtOAc gradient) yielded 2.334 
g of 2.13, which was recovered as an oily substance. 1H NMR (400 MHz, CDCl3) δ 5.20 – 
5.14 (m, 1H), 4.07 (dd, J = 10.4, 4.9, 1H), 3.77 – 3.57 (m, 3H), 3.40 (td, J = 10.0, 4.9, 1H), 
2.11 (s, 3H), 1.61 – 1.52 (m, 1H), 0.99 (s, 9H), 0.94 (s, 9H), 0.69 (dd, J = 8.7, 4.3, 2H). ESI-
MS calcd. for C17H30O5Si [M+Na
+] 365.19, found 365.13     
 
 
 
62 
 
(1R)-1-[(2,3,4-Trideoxy-(5S,6R)-5,7-di-tert-butylsilanediyl)-β-oxepinyl]thymine (2.14) 
 
Refluxed 4.824 g of thymine (38.25 mmol, 5.1 eq), 12.59 ml of HMDS, and 527 mg 
of (NH4)2SO4 in MeCN for four hours until solution became clear, which indicated that the 
nucleobase had been silylated. Removed solvent by rotary evaporation in a heated water 
bath. Transfer a solution of 2.13 (2.342 g, 7.56 mmol, 1 eq) in 25 mL of MeCN via a cannula 
into the flask containing the recently silylated nucleobase under an atosphere of N2. Once 
substrate 2.13 had been transferred, added 464 µL of TMSOTf dropwise. Reluxed reaction 
mixture overnight. When reaction had went to completion, as monitored by TLC, mixture 
was diluted with ethyl acetate. Addition of 5% NaHCO3 caused a white precipitate to form, 
which was then filtered off. The aqueous layers was drawn off in a separatory funnel, and the 
organic layer was susquently washed with brine, dried with MgSO4, and condensed down. 
The crude product was purified (20:1 to 2:1, hexanes/EtOAc gradient) by column 
chromatography and yielded 1.012 g of 2.14, β anomer, Rf  = 0.22 in 2:1 Hex:EtOAc. (α 
anomer, Rf  = 0.20 in 2:1 Hex:EtOAc) 
1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.19 (d, J 
= 1.0, 1H), 5.91 (dt, J = 12.2, 2.4, 1H), 5.73 (dd, J = 10.3, 1.6, 1H), 5.69 (dd, J = 7.4, 4.4, 1H), 
4.59 (dd, J = 9.2, 2.2, 1H), 4.06 (dd, J = 10.6, 4.8, 1H), 3.85 (t, J = 10.4, 1H), 3.68 – 3.57 (m, 
1H), 2.63 – 2.51 (m, 1H), 2.43 – 2.32 (m, 1H), 1.93 (d, J = 1.0, 3H), 1.05 (s, 9H), 0.98 (s, 9H). 
ESI-MS calcd. for C20H32N2O5Si  [M+Na
+] 431.21, found 431.18. 
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(1R,7S)-3-(Phenylthio)-9,9-di-tert-butyl-2,8,10-trioxa-9-silabicyclo[5.4.0]undec-5-ene 
(2.17) 
 
 
To a stirred solution of 2.13 (3.601 g, 10.50 mmol, 1 eq) in 30 mL of MeCN at 0 °C 
was added 4.96 mL of TMSSPh dropwise followed by 350 µL of TMSOTf under an 
atmosphere of N2. Reaction was ran overnight and quenched by the addition of 5% 
NaHCO3. Aqueous layer was extracted with ethyl acetate; organic extracts were washed with 
brine and dried over MgSO4. Flash chromatography of the crude (250:1 to 50:1 gradient, 
hexanes/EtOAc) yielded 3.358 g of 2.17, mixture of anomers, as an oil. 1H NMR (400 MHz, 
CDCl3) δ 7.48 – 7.41 (m, 4H), 7.36 – 7.21 (m, 6H), 5.88 – 5.81 (m, 1H), 5.79 (t, J = 2.2, 1H), 
5.72 – 5.62 (m, 2H), 5.45 (dd, J = 6.2, 4.4, 1H), 4.87 (dd, J = 9.9, 2.6, 1H), 4.66 – 4.59 (m, 
2H), 4.37 (td, J = 9.9, 4.9, 1H), 3.93 – 3.81 (m, 4H), 3.36 (dd, J = 16.2, 8.1, 1H), 2.85 – 2.52 
(m, 4H), 1.04 (s, 9H), 1.03 (s, 9H), 1.01 (s, 9H), 0.95 (s, 9H). ESI-MS calcd. for C21H32O3SSi 
[M-H+] 391.18, found 391.17. 
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(1R)-1-[(2,3,4-Trideoxy-(5S,6R)-5,7-di-tert-butylsilanediyl)-β-oxepinyl]thymine (2.14) 
 
 
 
 To a stirred solution of 2.17 (1.159 g, 2.95 mmol, 1 eq), thymine (0.744 g, 5.90 mmol, 
2 eq), and 200 mg of (NH4)2SO4 in 50 mL of DCM was added 0.793 mL of BSA dropwise 
under an atosphere of N2. Refluxed until solution became clear, cooled solution to ambient 
temperature, then added 2 g of 4 Å molecular sieves and 578 mg NBS (3.25 mmol, 1.1 eq). 
Refluxed reaction overnight and then quenched with 5% NaHCO3. Filtered reaction mixture 
over Celite filter aid. Extracted with ethyl acetate, washed organic extracts with brine and 
dried over MgSO4; condensed organic layer under reduced pressure. The crude product was 
purified (20:1 to 2:1, hexanes/EtOAc gradient) by column chromatography and yielded 
0.823 g of 2.14, β anomer, Rf  = 0.22 in 2:1 Hex:EtOAc. (α anomer, Rf  = 0.20 in 2:1 
Hex:EtOAc) 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.19 (d, J = 1.0, 1H), 5.91 (dt, J = 
12.2, 2.4, 1H), 5.73 (dd, J = 10.3, 1.6, 1H), 5.69 (dd, J = 7.4, 4.4, 1H), 4.59 (dd, J = 9.2, 2.2, 
1H), 4.06 (dd, J = 10.6, 4.8, 1H), 3.85 (t, J = 10.4, 1H), 3.68 – 3.57 (m, 1H), 2.63 – 2.51 (m, 
1H), 2.43 – 2.32 (m, 1H), 1.93 (d, J = 1.0, 3H), 1.05 (s, 9H), 0.98 (s, 9H). ESI-MS calcd. for 
C20H32N2O5Si  [M+Na
+] 431.21, found 431.18. 
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(1R)-1-[(2,3,4-Trideoxy-(5S,6R)-5-hydroxy-7-hydroxymethyl)-β-oxepinyl]thymine 
(2.15) 
 
 
 To a stirred solution of 767 mg of 2.14(1.88 mmol, 1 eq) in 5 mL of THF was added 
612 µL of TREAT-HF dropwise at 0 °C. After 3 hours, reaction was observed to go to 
completion. Solvent and residual TREAT-HF was removed by a rotary evaporator 
connected to an external vacuum pump. Purified crude product by flash chromatography 
(5% MeOH/DCM) and obtained 452 mg of 2.15. 1H NMR (400 MHz, DMSO-d6) δ 11.31 (s, 
1H), 7.60 (s, 1H), 5.77 – 5.71 (m, 1H), 5.67 – 5.54 (m, 2H),  4.03 (dd, J = 10.9, 4.6, 1H), 3.68 
– 3.61 (m, 1H), 3.47 – 3.36 (m, 2H), 3.16 (d, J = 5.3, 1H), 2.74 – 2.64 (m, 1H), 2.34 (m, 1H), 
1.78 (s, 3H), 1.56 (s, 1H). ESI-MS calcd. for C12H16N2O5 [M+Na
+] 291.11, found 291.14 
 
(1R)-1-[(2,3,4-Trideoxy-(5S,6R)-5-hydroxy-7-t-butyldiphenylsilyl)-β-oxepinyl]thymine 
(2.18) 
 
 
 To a stirred solution of 203 mg of 2.15 (0.76 mmol, 1 eq) and 77 mg of imidazole 
(1.13 mmol, 1.5 eq) in 5 mL of DMF was added 217 µL of TBDPSCl dropwise (0.83 mmol, 
1.1 eq) at 0 °C under an atmosphere of N2. Reaction was run overnight at room temperature 
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and quenched with 5% NaHCO3 solution. Extracted several times with ethyl acetate, washed 
organic extracts with brine, dried over MgSO4 and removed solvent in vacuo. Purification by 
flash chromatography (1% to 5% MeOH/DCM gradient) yielded 307 mg of 2.15. 1H NMR 
(400 MHz, CDCl3) δ 8.51 (s, 1H), 7.68 – 7.60 (m, 4H), 7.45 – 7.32 (m, 6H), 7.18 (s, 1H), 5.85 
(dt, J = 12.3, 2.5, 1H), 5.77 – 5.71 (m, 1H), 5.70 – 5.61 (m, 1H), 4.54 (dd, J = 8.9, 2.2, 1H), 
3.97-3.82 (m, 3H), 3.65 (dt, J = 9.3, 4.7, 1H), 2.59 – 2.36 (m, 2H), 1.87 (d, J = 1.1, 3H), 1.04 
(s, 9H). ESI-MS calcd. for C28H34N2O5Si [M+Na
+] 529.22, found 529.21. 
4.3 Chapter 3 Characterization 
 
5'-O-Monomethoxytrityl-β-D-uridine (3.4)  
 
 
 To a stirred solution of 3.022 g of 3.3 (12.38 mmol, 1 eq) in 60 mL of anhydrous 
pyridine was added (via cannula transfer) a solution of 4.185 g of MMTrCl (13.55 mmol, 1.09 
eq) under an atmosphere of nitrogen. After running reaction overnight at room temperature, 
a 5% NaHCO3 solution was added as a quench and reaction was stirred for an additional 15 
minutes. Most of the pyridine was then removed by rotary evaporation; and the residue was 
dissolved in DCM. Organic layer was washed with water and brine, dried over MgSO4 and 
finally condensed down. Purification by column chromatography (2% to 5% MeOH/DCM 
gradient) afforded 5.467 g of 3.4 as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 
1H), 7.72 (d, J = 8.0, 1H), 7.41 – 7.21 (m, 12H), 6.92 (d, J = 8.9, 2H), 5.74 (d, J = 3.1, 1H), 
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5.53 (d, J = 4.6, 1H), 5.31 (d, J = 8.0, 1H), 5.18 (d, J = 5.5, 1H), 4.12 – 4.04 (m, 2H), 3.95 (d, 
J = 2.7, 1H), 3.75 (s, 3H), 3.31 – 3.17 (m, 2H). ESI-MS calcd. for C29H28N2O7  [M+Na
+] 
539.19, found 539.18. 
 
1-{1-[1-(4,4'-Monomethoxytrityloxymethyl)prop-2-enyloxy]prop-2-enyl}uracil (3.5) 
 
 
  
 To a stirred solution of 582.6 mg of 3.4 (1.13 mmol, 1 eq) in 10 mL of dioxane was 
added 280.1 mg of NaIO4 (suspended in 2 mL of H2O) dropwise.  Reaction proceeded at 
room temperature for 3 hours and then was diluted with 10 mL of dioxane. After filtering 
over Celite filter aid, the reaction was worked-up with DCM and brine, dried over MgSO4 
and condensed down. Residues were dried by azeotropic condensation from benzene and 
then dissolved in 60 mL of anhydrous benzene. Solution was then refluxed and 40 mL were 
removed via a Dean-Stark trap over a 2 hour period in order to dehydrate dioxane ring. 
Residual amount of benzene was removed by rotary evaporation, and the residue was 
subjected to high-vacuum until used in section below.  
To a stirred suspension of 4.577 g of dry methyltriphenylphosphonium bromide in 
13 mL of anhydrous THF was added 12 mL of 1M KOtBu solution dropwise at 0 °C. 
Reaction was allowed to stir for 1 hour at room temperature; resulting yellow solution was 
the 0.50 M ylide solution used below. 
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To a stirred solution of 1 mmol of dialdehyde intermediate (generated in first part) in 
10 mL of THF was added 10 mL of 0.50 M ylide solution (5 mmol, 1 eq) dropwise at 0 °C. 
Reaction was stirred for 1 hour 15 minutes at room temperature, at which point complete 
consumption of starting material was observed. Water was added to reaction mixture using a 
Pasteur pipette until yellow color disappeared in order to quench excess ylide. Diluted 
reaction mixture with DCM and washed with saturated NH4Cl solution and with brine. 
Extracted aqueous layers with DCM, dried pooled organic extracts over MgSO4, and 
condensed down to an oil. Purification by flash chromatography (isocratic 3:2 
hexanes/EtOAc) yielded 125 mg of 3.5. It should be noted that under these conditions 
another compound co-elutes with the desired 3.5 and is possibly an isomerized epimer of 3.5. 
See discussion of potential enolization of dialdehyde in section 3.2.4. 1H NMR (400 MHz, 
CDCl3) δ 8.23 (s, 1H), 7.48 (d, J = 8.1, 1H), 7.42 – 7.35 (m, 4H), 7.29 – 7.24 (m, 7H), 7.21 (d, 
J = 2.3, 1H), 6.80 (d, J = 8.9, 2H), 6.23 – 6.20 (m, 1H), 5.69 (dd, J = 8.1, 2.3, 1H), 5.59 (dd, J 
= 17.2, 10.1, 3H), 5.41 (d, J = 10.5, 1H), 5.30 (d, J = 4.0, 1H), 5.26 (s, 1H), 3.87 (d, J = 2.8, 
1H), 3.78 (s, 3H), 3.32 (dd, J = 10.4, 8.2, 1H), 3.03 (dd, J = 10.5, 3.1, 1H). ESI-MS calcd. for 
C31H30N2O5 [M+Na
+] 533.22, found 533.11. For an alternative procedure and for spectra of 
similar compounds, see synthesis of d4T.88  
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5'-O-Monomethoxytrityl-2',3'-seco-β-D-uridine (3.9) 
 
 
To a stirred solution of 2.759 g of 3.4 (5.35 mmol, 1 eq) in 25 mL of dioxane was 
added 1.2622 g of NaIO4 (5.89 mmol, 1.1 eq) and 5 mL of water. When oxidative cleavage 
had gone to completion, as monitored by TLC, within 3 hours, the reaction mixture was 
diluted with an additional 25 mL of dioxane. Filtered diluted reaction mixture and added 
228.5 mg (5.91 mmol, 1.1 eq) of NaBH4. Reduction was allowed to proceed to completion, 
about 20 minutes, at room temperature. Acetone (10 mL) was added to quench excess 
reducing agent and reaction was stirred for an additional 10 minutes. A small amount of 
saturated NH4Cl was added to neutralize reaction mixture, and solvent volume of reaction 
mixture was decreased to around 15 mL by rotary evaporation. (Alternatively, dioxane can be 
removed under reduced pressure and NH4Cl neutralization can be done in work-up.) 
Reaction mixture was diluted with DCM, washed with water and brine, dried over MgSO4 
and condensed down. Recovered 2.713 g of 3.9 as a white foam; reaction proceeds cleanly 
and column chromatography is unnecessary. 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 
7.64 (d, J = 8.0, 1H), 7.34 – 7.19 (m, 10H), 7.17 (d, J = 8.9, 2H), 6.87 (d, J = 8.9, 2H), 5.81 (t, 
J = 5.8, 1H), 5.52 (d, J = 8.0, 1H), 5.13 (t, J = 5.9, 1H), 4.75 (t, J = 5.5, 1H), 3.74 (s, 3H), 3.71 
– 3.52 (m, 3H), 3.40 (t, J = 5.2, 2H), 3.04 – 2.88 (m, 2H). ESI-MS calcd. for C29H30N2O7  
[M+Na+] 541.21, found 541.19. 
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5'-O-Monomethoxytrityl-2',3'-O-dimesyl-seco-β-D-uridine (3.10) 
 
 
 
 To a stirred solution of 303.1 mg of 3.9 (0.59 mmol, 1 eq) in 5 mL of pyridine at 
0 °C was added 200 µL of MsCl. Reaction was stirred for 2.5 hours at 0 °C and then solvent 
was removed by rotary evaporation. Dissolved residue in DCM, washed with water and brine, 
dried over MgSO4 and condensed down. Purification by column chromatography (0% to 5% 
MeOH/DCM gradient) yielded 319 mg of 3.10 as a white foam. 1H NMR (400 MHz, 
DMSO-d6) δ 11.49 (d, J = 1.9, 1H), 7.70 (d, J = 8.1, 1H), 7.36 – 7.15 (m, 12H), 6.91 – 6.85 
(m, 2H), 6.05 (t, J = 5.7, 1H), 5.57 (dd, J = 8.0, 2.1, 1H), 4.49 (d, J = 5.6, 2H), 4.41 – 4.25 (m, 
2H), 3.74 (s, 3H), 3.22 (s, 3H), 3.16 (s, 3H), 3.15 – 2.97 (m, 3H). ESI- MS calcd. for 
C31H34N2O11S2 [M+Na
+] 697.16, found 697.05.  
 
5'-O-Monomethoxytrityl-2',3'-seco-β-D-(N3-p-methoxybenzyl)-uridine (3.11) 
 
 
 To a stirred solution of 2.161 g of 3.9 (4.17 mmol, 1 eq) in 42 mL of acetonitrile was 
added 1.25 mL of DBU (8.35 mmol, 2 eq) dropwise followed by 1.02 mL of PMBCl (7.52 
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mmol, 1.8 eq) dropwise. Heated reaction mixture to 60 °C and stirred reaction for 1 hour.  
Diluted with DCM and washed organic layer with 5% NaHCO3 and brine. Dried organic 
layer over MgSO4 and condensed. Neutralized silica gel with 1% NEt3/DCM and purified 
crude reaction mixture by flash chromatography (1% to 3% MeOH/DCM gradient). 
Recovered 1.869 g of 3.11, which was a white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.67 
(d, J = 8.0, 1H), 7.30 – 7.15 (m, 12H), 7.12 (d, J = 8.8, 2H), 6.81 (d, J = 8.9, 2H), 6.76 (d, J = 
8.7, 2H), 5.85 (t, J = 5.7, 1H), 5.66 (d, J = 8.0, 1H), 5.12 (t, J = 6.0, 1H), 4.91 (abq, J = 14.1, 
2H), 4.75 (t, J = 5.5, 1H), 3.71 (s, 3H), 3.64 (s, 3H), 3.69 – 3.50 (m, 3H), 3.40 (t, J = 5.3, 2H), 
3.00 – 2.92 (m, 2H). ESI-MS calcd. for C37H38N2O8 [M+Na
+] 661.26, found 661.27. 
 
 5'-O-Monomethoxytrityl-2',3'-O-ditosyl-seco-β-D-(N3-p-methoxybenzyl)-uridine 
(3.12) 
 
 
 To a stirred solution of 1.552 g of 3.11 (2.4 mmol, 1 eq) in 10 mL of pyridine added a 
second solution of 1.858 g of TsCl in 10 mL of pyridine (9.75 mmol, 4.06 eq) via cannula 
transfer under atmosphere of N2 flow. Reaction was run overnight at room temperature. 
Diluted with DCM and worked up with 5% NaHCO3 and brine solutions. (Alternatively, 
pyridine can be removed first and residue dissolved in DCM.) Organic layer was dried over 
MgSO4 and condensed down. Purification by column chromatography (0.5% to 1% 
acetone/DCM) afforded 1.794 g of 3.12 as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 
7.71 (d, J = 8.3, 2H), 7.63 (d, J = 8.3, 2H), 7.45 – 7.39 (m, 3H), 7.32 (d, J = 8.1, 2H), 7.23 – 
72 
 
7.12 (m, 7H), 7.02 (dd, J = 8.9, 2.6, 4H), 6.78 (d, J = 8.7, 6H), 5.87 (t, J = 5.2, 1H), 5.50 (d, J 
= 8.1, 1H), 4.77 (abt, j = 16, 2H), 4.32 – 4.24 (m, 1H), 4.19 – 3.92 (m, 3H), 3.75-3.70 (m, 2H), 
3.72 (s, 3H), 3.67 (s, 3H), 2.94 – 2.78 (m, 2H), 2.39 (s, 3H), 2.37 (s, 3H). ESI- MS calcd. for 
C51H50N2O12S2 [M+Na
+] 969.28, found  969.13. 
 
5'-O-Monomethoxytrityl-2',3'-O-di-iodo-seco-β-D-(N3-p-methoxybenzyl)-uridine 
(3.15) 
 
 To a stirred solution of 1.173 g  of 3.12 (1.24 mmol, 1 eq) in 25 mL of dry acetone 
was added 829.7 mg of previously dried NaI. Reaction was run under reflux conditions 
overnight. Reaction mixture was then diluted with DCM, and sodium tosylate precipitate was 
filtered off. Washed organic layer with brine; extracted aqueous layers with DCM. Dried 
organic extracts over MgSO4, and condensed pooled organic fractions. Recoverd 982 mg of 
3.15 as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 8.1, 1H), 7.31 – 7.12 (m, 
14H), 6.84 (d, J = 8.9, 2H), 6.79 (d, J = 8.7, 2H), 5.97 (t, J = 6.5, 1H), 5.76 (d, J = 8.0, 1H), 
4.97 – 4.86 (m, 2H), 3.73 (s, 3H), 3.66 (s, 3H), 3.62 – 3.39 (m, 5H), 3.12 – 2.94 (m, 2H). ESI-
MS calcd. for C37H36I2N2O6 [M+Na
+] 881.07, found 881.03. 
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5'-O-Monomethoxytrityl-2',3'-O-di-iodo-seco-β-D-(N3-p-methoxybenzyl)-uridine 
(3.15) 
 
 
 To a stirred solution of 1.09 g of 3.13 (1.71 mmol, 1 eq), 1.361 g of 
triphenylphosphine (5.14 mmol, 3.0 eq), and 1.170 g of imidazole (17.09 mmol, 10 eq) in 15 
mL of DCM was added 1.3061 g of I2 (5.05 mmol, 2.95 eq) at added at 0 °C. Reaction was 
allowed to react at room temperature for 2 hours; reaction was then cooled to 0 °C and 
another 2 equivalents of PPh3 and I2 were added. Reaction was then run overnight at room 
temperature and then diluted with DCM. Organic layer was quenched with aqueous sodium 
thiosulfate, washed with brine, dried over MgSO4 and finally condensed down. Purification 
by column chromatography (4:1 to 7:3 hexane/EtOAc gradient) yielded 1.251 g of 3.15 as a 
white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 8.1, 1H), 7.31 – 7.12 (m, 14H), 
6.84 (d, J = 8.9, 2H), 6.79 (d, J = 8.7, 2H), 5.97 (t, J = 6.5, 1H), 5.76 (d, J = 8.0, 1H), 4.97 – 
4.86 (m, 2H), 3.73 (s, 3H), 3.66 (s, 3H), 3.62 – 3.39 (m, 5H), 3.12 – 2.94 (m, 2H). ESI-MS 
calcd. for C37H36I2N2O6 [M+Na
+] 881.07, found 881.03. 
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5'-O-Monomethoxytrityl-2',3'-O-dichloro-seco-β-D-(N3-p-methoxybenzyl)-uridine 
(3.16) 
 
 To a stirred solution of 1.869 g of 3.13 (2.93 mmol, 1 eq), 3.117 g of 
triphenylphosphine (11.8 mmol, 4.02 eq) and 404.8 mg (5.92 mmol, 2.02 eq) in 16 mL of 
DCM was added 3.4 mL of CCl4 (35.23 mmol, 12.03 eq) dropwise at 0 °C under an 
atmosphere of N2. Reaction was allowed to proceed at room temperature overnight and then 
condensed down to a white foam. Purification of the crude reaction mixture by column 
chromatography (10% to 30% EtOAc/hexanes gradient) afforded 1.583 g of 3.16 as a white 
foam. 1H NMR (400 MHz, DMSO-d6) δ 7.78 (d, J = 8.1, 1H), 7.31 – 7.18 (m, 12H), 7.15 (d, 
J = 8.8, 2H), 6.84 (d, J = 8.9, 2H), 6.78 (d, J = 8.7, 2H), 6.06 (t, J = 6.2, 1H), 5.76 (d, J = 8.1, 
1H), 4.91 (abq, J = 14.2, 2H), 4.01 (qd, J = 12.0, 6.3, 2H), 3.89 – 3.79 (m, 3H), 3.73 (s, 3H), 
3.67 (s, 3H), 3.15 – 3.00 (m, 2H). ESI-MS calcd. for C37H36Cl2N2O6 [M+Na
+] 697.20, found 
697.19. 
5'-O-Monomethoxytrityl-2',3'-O-dibromo-seco-β-D-(N3-p-methoxybenzyl)-uridine 
(3.19) 
 
 To a stirred solution of 1.218 g of 3.13 (1.90 mmol, 1 eq), 259 mg of imidazole (3.79 
mmol, 2 eq), and 2.535 g of CBr4 (7.56 mmol, 3.98 eq) in 20 mL of anhydrous THF was 
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added a second solution of 2.010 g PPh3 (7.58 mmol, 4 eq) in 5 mL of THF dropwise at 0 °C. 
Reaction was stirred for 1.5 hour at room temperature then diluted with DCM. Organic layer 
was washed with brine, dried over MgSO4 and condensed. Neutralized silica gel with 1% 
NEt3/DCM and purified by column chromatography (9:1 to 4:1 hexanes/EtOAc gradient). 
Recovered 1.128 g of 3.19 as a foam. 1H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 8.1, 1H), 
7.29 – 7.17 (m, 12H), 7.12 (d, J = 8.9, 2H), 6.82 (d, J = 8.8, 2H), 6.76 (d, J = 8.6, 2H), 6.05 (s, 
1H), 5.74 (d, J = 8.1, 1H), 4.95 – 4.83 (abq, 2H), 3.94 – 3.87 (m, 1H), 3.82 (dd, J = 10.6, 5.4, 
2H), 3.71 (s, 3H), 3.68 (d, J = 4.4, 2H), 3.64 (s, 4H), 3.12 – 3.00 (m, 2H). ESI-MS calcd. For 
C37H36Br2N2O6  [M+Na
+] 785.08, found 784.98. 
 
7'-O-Monomethoxytrityl-2,5-dihydroxy- β-oxepinyl-uridine (3.21) 
 
 
 To a stirred solution of 1.1026 g of 3.3 (2.14 mmol, 1 eq) in 20 mL of dioxane was 
added 502.9 mg of NaIO4 (suspended in 4 mL of H2O) dropwise.  Reaction proceeded at 
room temperature for 3 hours and then was diluted with 20 mL of dioxane. After filtering 
over Celite filter aid, the reaction was worked-up with DCM and brine, dried over MgSO4 
and condensed down. Residues were dried by azeotropic condensation from benzene and 
used in the next step without further purification.  
 To a stirred solution of 380.8 mg (0.74 mmol, 1 eq) of previously generated 
dialdehyde intermediate in 3 mL of THF was added 3.7 mL of 1 M vinylmagnesium bromide 
solution (3.7 mmol, 5 eq) dropwise at -78 °C under an atmosphere of N2. Reaction was 
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stirred for 2 hours 40 minutes at -78 °C, and then it was allowed to warm to 0 °C. At 0 °C, 
the reaction mixture was quenched with saturated NH4Cl solution, diluted with DCM. 
Organic layer was washed with brine, dried over MgSO4 and condensed down. A filter 
column (2.5% to 7% gradient MeOH/DCM) was performed on the reaction mixture. The 
product was immediately used in the next step.  
 To a stirred solution 170 mg (0.3 mmol) of the previously obtained intermediate in 
30 mL of anhydrous DCM was added 25 mg of Grubbs II (0.03 mmol, 10 mol %) Reaction 
was stirred at room temperature for 48 hours, diluted with DCM, worked up and purified. 
On TLC purified reaction product ran as one spot, but examination of 1H NMR indicated 
that multiple compounds were present (the various diastereomers) precluding full spectral 
analysis. ESI-MS calcd. for C31H30N2O7 [M+Cl
-] 577.17, found 577.08; [M-H+] 541.20, found 
541.20. HRMS calcd. for C31H30N2O7 [M-H
+] 541.19693, found 541.19800, supporting 
elemental composition.  
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Contribution to Knowledge 
 
 
Since nucleosides, nucleoside analogues and oligonucleotides have such great 
potential as therapeutic agents, their study is not only academically interesting but also 
directly tied to potential medicinal applications. This thesis describes work towards 
developing novel routes in the synthesis of seven-membered (oxepane) nucleosides. In 
chapter 2, studies on the synthesis of oxepane nucleosides by a ring-expansion route were 
described, building on previous work done in the Damha lab. While this approach was a 
viable route to the synthesis of oxepane nucleoside, it was low-yielding in the key 
glycosylation step. To improve this crucial step, thioglycoside intermediates were used in the 
synthesis of oxepane nucleosides. Initial work towards the synthesis of dihydroxylated 
monomers was carried, but was eventually set aside for the examination RCM-based routes. 
Grubbs catalyst mediated ring-closing metathesis is an effective synthetic methodology in the 
formation of rings, and so it was surmised that oxepane nucleosides could be made by this 
approach. In chapter 3, studies on the development of synthetic routes for oxepanes are 
described. Synthetic routes involving Wittig chemistry, Grignard chemistry, organocopper 
chemistry, nitrile chemistry were explored. In particular, the direct addition of vinyl 
magnesium bromide to nucleoside dialdehydes, followed by Grubbs II mediated ring 
metathesis served as a proof-of-principle for the synthesis of oxepane nucleosides by a ring 
closing approach. In the course of these syntheses, novel acyclic nucleosides, which could be 
assayed for antiviral and anticancer activity, were also synthesized.  
 
 
   
78 
 
References 
 
 
 (1) Maderspacher, F. Current Biology 2004, 14, R608. 
 (2) Avery, O. T.; MacLeod, C. M.; McCarty, M. J. Exp. Med. 1944, 79, 137. 
 (3) Watson, J. D.; Crick, F. H. C. Nature (London, U. K.) 1953, 171, 737. 
 (4) Wilkins, M. H. F.; Stokes, A. R.; Wilson, H. R. Nature 1953, 171, 738. 
 (5) Chargaff, E.; Lipshitz, R.; Green, C.; Hodes, M. E. J. Biol. Chem. 1951, 192, 
223. 
 (6) Crick, F. H. C.; Watson, J. D. Proc. R. Soc. London, Ser. A 1954, 223, 80. 
 (7) Blackburn, G. M.; Gait, M. J. Nucleic acids in chemistry and biology; IRL Press at 
Oxford University Press: Oxford; New York, 1990. 
 (8) Rohs, R.; Jin, X.; West, S. M.; Joshi, R.; Honig, B.; Mann, R. S. Annu. Rev. 
Biochem. 2010, 79, 233. 
 (9) Rich, A.; Zhang, S. Nat Rev Genet 2003, 4, 566. 
 (10) Bessman, M. J.; Lehman, I. R.; Simms, E. S.; Kornberg, A. Journal of Biological 
Chemistry 1958, 233, 171. 
 (11) Lehman, I. R.; Bessman, M. J.; Simms, E. S.; Kornberg, A. Journal of Biological 
Chemistry 1958, 233, 163. 
 (12) Crick, F. Nature 1970, 227, 561. 
 (13) Hoagland, M. B.; Stephenson, M. L.; Scott, J. F.; Hecht, L. I.; Zamecnik, P. C. 
J. Biol. Chem. 1958, 231, 241. 
 (14) Cech, T. R. Science 2000, 289, 878. 
 (15) Ogawa, T.; Okazaki, T. Annu Rev Biochem 1980, 49, 421. 
 (16) Michelson, A. M.; Todd, A. R. J. Chem. Soc. 1955, 2632. 
79 
 
 (17) Khorana, H. Science 1979, 203, 614. 
 (18) Khorana, H. G.; Agarwal, K. L.; Büchi, H.; Caruthers, M. H.; Gupta, N. K.; 
Klbppe, K.; Kumar, A.; Ohtsuka, E.; RajBhandary, U. L.; van de Sande, J. H.; Sgaramella, V.; 
Tebao, T.; Weber, H.; Yamada, T. Journal of Molecular Biology 1972, 72, 209. 
 (19) Beaucage, S. L.; Caruthers, M. H. Tetrahedron Lett. 1981, 22, 1859. 
 (20) Pon, R. T.; CRC Press LLC: 2003, p 1. 
 (21) Corey, E. J.; Venkateswarlu, A. Journal of the American Chemical Society 1972, 94, 
6190. 
 (22) Ogilvie, K. K.; Usman, N.; Nicoghosian, K.; Cedergren, R. J. Proceedings of the 
National Academy of Sciences of the United States of America 1988, 85, 5764. 
 (23) Caruthers, M. H. Accounts of Chemical Research 1991, 24, 278. 
 (24) Zamecnik, P. C.; Stephenson, M. L. Proceedings of the National Academy of Sciences 
of the United States of America 1978, 75, 280. 
 (25) Mangos Maria, M.; Damha Masad, J. Curr Top Med Chem 2002, 2, 1147. 
 (26) Kurreck, J. Eur. J. Biochem. 2003, 270, 1628. 
 (27) Watts, J. K.; Corey, D. R. Bioorganic & Medicinal Chemistry Letters 2010, 20, 
3203. 
 (28) Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. 
Nature 1998, 391, 806. 
 (29) Jinek, M.; Doudna, J. A. Nature 2009, 457, 405. 
 (30) Haussecker, D. Hum. Gene Ther. 2008, 19, 451. 
 (31) Watts, J. K.; Deleavey, G. F.; Damha, M. J. Drug Discovery Today 2008, 13, 842. 
 (32) Alberts, B. Molecular biology of the cell; Garland Science: New York, 2002. 
 (33) Mathé, C.; Gosselin, G. Antiviral Research 2006, 71, 276. 
80 
 
 (34) Hajos, Z. G.; Wachter, M. P.; Adams, R. E.; Werblood, H. M. Synth. Commun. 
1989, 19, 2891. 
 (35) Chen, R.; Rowand, D. A. J. Am. Chem. Soc. 1980, 102, 6609. 
 (36) Aydogmus, Z.; Imre, S.; Ersoy, L.; Wray, V. Nat. Prod. Res. 2004, 18, 43. 
 (37) Guella, G.; Pietra, F. Helv. Chim. Acta 1991, 74, 47. 
 (38) Kadota, I.; Abe, T.; Uni, M.; Takamura, H.; Yamamoto, Y. Tetrahedron Lett. 
2008, 49, 3643. 
 (39) Takamura, H.; Kikuchi, S.; Nakamura, Y.; Yamagami, Y.; Kishi, T.; Kadota, I.; 
Yamamoto, Y. Organic Letters 2009, 11, 2531. 
 (40) Yazbeck, D. R.; Min, K.-L.; Damha, M. J. Nucleic Acids Res. 2002, 30, 3015. 
 (41) Bolli, M.; Micura, R.; Eschenmoser, A. Chemistry & Biology 1997, 4, 309. 
 (42) Sabatino, D.; Damha, M. J. Journal of the American Chemical Society 2007, 129, 
8259. 
 (43) Hoberg, J. O. The Journal of Organic Chemistry 1997, 62, 6615. 
 (44) Hoberg, J. O. Carbohydr. Res. 1997, 300, 365. 
 (45) Gabrielli, G.; Melani, F.; Bernasconi, S.; Lunghi, C.; Richichi, B.; Rollin, P.; 
Venturi, C.; Nativi, C. J. Carbohydr. Chem. 2009, 28, 124. 
 (46) Hoveyda, A. H.; Evans, D. A.; Fu, G. C. Chem. Rev. (Washington, D. C.) 1993, 
93, 1307. 
 (47) Simmons, H. E.; Smith, R. D. Journal of the American Chemical Society 1958, 80, 
5323. 
 (48) Furukawa, J.; Kawabata, N.; Nishimura, J. Tetrahedron 1968, 24, 53. 
 (49) Kawabata, N.; Nakagawa, T.; Nakao, T.; Yamashita, S. The Journal of Organic 
Chemistry 1977, 42, 3031. 
81 
 
 (50) Ferrier, R. J.; Overend, W. G.; Ryan, A. E. J. Chem. Soc. 1962, 3667. 
 (51) Ferrier, R. J. J. Chem. Soc. 1964, 5443. 
 (52) Sugimura, H.; Osumi, K.; Kodaka, Y.; Sujino, K. The Journal of Organic 
Chemistry 1994, 59, 7653. 
 (53) Sugimura, H. Noguchi Kenkyusho Jiho 1992, 35, 5. 
 (54) Demchenko, A.; Stauch, T.; Boons, G. J. Synlett 1997, 818. 
 (55) Oscarson, S.; Wiley-VCH Verlag GmbH: 2000; Vol. 1, p 93. 
 (56) Codee, J. D. C.; Litjens, R. E. J. N.; Van, d. B. L. J.; Overkleeft, H. S.; Van, d. 
M. G. A. Chem. Soc. Rev. 2005, 34, 769. 
 (57) Hanessian, S.; Bacquet, C.; Lehong, N. Carbohydr. Res. 1980, 80, C17. 
 (58) Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1 1975, 1574. 
 (59) Myers, A. G.; Movassaghi, M.; Zheng, B. Journal of the American Chemical Society 
1997, 119, 8572. 
 (60) Evans, D. A.; Fu, G. C.; Hoveyda, A. H. Journal of the American Chemical Society 
1988, 110, 6917. 
 (61) Swamy, K. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. 
Chemical Reviews 2009, 109, 2551. 
 (62) Tracy Yuen Sze But, Patrick H. T. Chemistry - An Asian Journal 2007, 2, 1340. 
 (63) Roman, D. European Journal of Organic Chemistry 2004, 2004, 2763. 
 (64) Mitsunobu, O. Synthesis 1981, 1. 
 (65) Dodge, J. A.; Lugar, C. W., III Bioorg. Med. Chem. Lett. 1996, 6, 1. 
 (66) Yan, L.; Kahne, D. Journal of the American Chemical Society 1996, 118, 9239. 
 (67) Toshima, K.; Tatsuta, K. Chemical Reviews 1993, 93, 1503. 
82 
 
 (68) García, J.; Díaz-Rodríguez, A.; Fernández, S.; Sanghvi, Y. S.; Ferrero, M.; 
Gotor, V. The Journal of Organic Chemistry 2006, 71, 9765. 
 (69) Evans, D. A.; Fu, G. C.; Anderson, B. A. Journal of the American Chemical Society 
1992, 114, 6679. 
 (70) Evans, D. A.; Fu, G. C.; Hoveyda, A. H. Journal of the American Chemical Society 
1992, 114, 6671. 
 (71) Evans, D. A.; Fu, G. C. The Journal of Organic Chemistry 1990, 55, 2280. 
 (72) Trnka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18. 
 (73) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413. 
 (74) Connon, S. J.; Blechert, S. Angew Chem Int Ed Engl 2003, 42, 1900. 
 (75) Dvorak, C. A.; Schmitz, W. D.; Poon, D. J.; Pryde, D. C.; Lawson, J. P.; 
Amos, R. A.; Meyers, A. I. Angew. Chem., Int. Ed. 2000, 39, 1664. 
 (76) Crimmins, M. T.; Tabet, E. A. Journal of the American Chemical Society 2000, 122, 
5473. 
 (77) Petersen, M.; Nielsen, P. The Journal of Organic Chemistry 2006, 71, 7731. 
 (78) Sorensen, A. M.; Nielsen, P. Organic Letters 2000, 2, 4217. 
 (79) Borsting, P.; Christensen, M. S.; Steffansen, S. I.; Nielsen, P. Tetrahedron 2006, 
62, 1139. 
 (80) Vrcek, V.; Caplar, V. Tetrahedron Lett. 1994, 35, 3987. 
 (81) Vrcek, V.; Caplar, V. Helv. Chim. Acta 1995, 78, 1797. 
 (82) Van Aerschot, A.; Balzarini, J.; De Clercq, E.; Herdewijn, P. Nucleosides 
Nucleotides 1991, 10, 591. 
 (83) Prisbe, E. J. J. Med. Chem. 1986, 29, 2445. 
83 
 
 (84) Kenski, D. M.; Cooper, A. J.; Li, J. J.; Willingham, A. T.; Haringsma, H. J.; 
Young, T. A.; Kuklin, N. A.; Jones, J. J.; Cancilla, M. T.; McMasters, D. R.; Mathur, M.; 
Sachs, A. B.; Flanagan, W. M. Nucleic Acids Res 2010, 38, 660. 
 (85) Maggio, A. F.; Boyer, V.; Aubertin, A. M.; Obert, G.; Kirn, A.; Imbach, J. L. 
Nucleosides Nucleotides 1991, 10, 1431. 
 (86) Mangos, M. M.; Min, K.-L.; Viazovkina, E.; Galarneau, A.; Elzagheid, M. I.; 
Parniak, M. A.; Damha, M. J. Journal of the American Chemical Society 2003, 125, 654. 
 (87) Maryanoff, B. E.; Reitz, A. B. Chem. Rev. 1989, 89, 863. 
 (88) Ewing, D. F.; Glaçon, V.; Mackenzie, G.; Postel, D.; Len, C. Tetrahedron 2003, 
59, 941. 
 (89) Ewing, D.; Glacon, V.; Mackenzie, G.; Postel, D.; Len, C. Tetrahedron Lett. 
2002, 43, 3503. 
 (90) Howarth, O.; Jones, A. S.; Walker, R. T.; Wyatt, P. G. J. Chem. Soc., Perkin 
Trans. 2 1984, 261. 
 (91) Schlosser, M.; Christmann, K. F. Angewandte Chemie International Edition in 
English 1964, 3, 636. 
 (92) Kabalka, G. W.; Shoup, T. M.; Goudgaon, N. M. J. Org. Chem. 1989, 54, 5930. 
 (93) Kabalka, G. W.; Yu, S.; Li, N.-S. Tetrahedron Lett. 1997, 38, 5455. 
 (94) Brown, H. C.; Liotta, R.; Brener, L. Journal of the American Chemical Society 1977, 
99, 3427. 
 (95) Brown, H. C.; Liotta, R.; Scouten, C. G. Journal of the American Chemical Society 
1976, 98, 5297. 
 (96) Fuson, R. C.; Mon, M. T. J. Org. Chem. 1961, 26, 756. 
 (97) Lai, Y.-H. Synthesis 1981, 585. 
84 
 
 (98) Furneaux, R. H.; Gainsford, G. J.; Mason, J. M.; Tyler, P. C. Tetrahedron 1994, 
50, 2131. 
 (99) Kumar, A.; Walker, R. T. Tetrahedron 1990, 46, 3101. 
 (100) Whitesides, G. M.; Fischer, W. F., Jr.; San, F. J., Jr.; Bashe, R. W.; House, H. 
O. J. Amer. Chem. Soc. 1969, 91, 4871. 
 (101) Lipshutz, B. H.; Wilhelm, R. S.; Floyd, D. M. J. Am. Chem. Soc. 1981, 103, 
7672. 
 (102) House, H. O.; Chu, C.-Y.; Wilkins, J. M.; Umen, M. J. The Journal of Organic 
Chemistry 1975, 40, 1460. 
 (103) Normant, J. F. Synthesis 1972, 63. 
 (104) Johnson, C. R.; Dutra, G. A. Journal of the American Chemical Society 1973, 95, 
7777. 
 (105) Johnson, C. R.; Dutra, G. A. Journal of the American Chemical Society 1973, 95, 
7783. 
 (106) Jones, S. S.; Reese, C. B.; Sibanda, S.; Ubasawa, A. Tetrahedron Lett. 1981, 22, 
4755. 
 (107) Sekine, M. The Journal of Organic Chemistry 1989, 54, 2321. 
 (108) Schulz, B. S.; Pfleiderer, W. Tetrahedron Lett. 1983, 24, 3587. 
 (109) Akiyama, T.; Nishimoto, H.; Ozaki, S. Bull. Chem. Soc. Jpn. 1990, 63, 3356. 
 (110) Danishefsky, S. J.; DeNinno, S. L.; Chen, S. H.; Boisvert, L.; Barbachyn, M. 
Journal of the American Chemical Society 1989 
111, 5810. 
 (111) Kabalka, G. W.; Varma, M.; Varma, R. S.; Srivastava, P. C.; Knapp, F. F. The 
Journal of Organic Chemistry 1986, 51, 2386. 
85 
 
 (112) Toth, J. E.; Hamann, P. R.; Fuchs, P. L. The Journal of Organic Chemistry 1988, 
53, 4694. 
 (113) Kofron, W. G.; Baclawski, L. M. The Journal of Organic Chemistry 1976, 41, 1879. 
 (114) Kiljunen, H.; Hase, T. A. The Journal of Organic Chemistry 1991, 56, 6950. 
 (115) Suffert, J. The Journal of Organic Chemistry 1989, 54, 509. 
 (116) Lipton, M. F.; Sorensen, C. M.; Sadler, A. C.; Shapiro, R. H. J. Organomet. 
Chem. 1980, 186, 155. 
 (117) Kauffman, G. B.; Pinnell, R. P. Inorganic Syntheses (Eugene G. Rochow, editor, 
McGraw-Hill Book Co.) 1960, 6, 3. 
 (118) Gilman, H.; Schulze, F. Journal of the American Chemical Society 1925, 47, 2002. 
 (119) Whitesides, G. M.; Casey, C. P.; Krieger, J. K. J. Amer. Chem. Soc. 1971, 93, 
1379. 
 (120) House, H. O.; DuBose, J. C. J. Org. Chem. 1975, 40, 788. 
 (121) Finkelstein, H. Ber. Dtsch. Chem. Ges. 1910, 43, 1528. 
 (122) Kauffman, G. B.; Teter, L. A. Inorg. Syn. (Jacob Kleinberg, editor. McGraw) 1963, 7, 
9. 
 (123) Pan, V.; Hutchinson, D. K.; Nantz, M. H.; Fuchs, P. L. Tetrahedron 1989, 45, 
467. 
 (124) Lipshutz, B. H.; Parker, D.; Kozlowski, J. A.; Miller, R. D. J. Org. Chem. 1983, 
48, 3334. 
 (125) Lipshutz, B. H.; Wilhelm, R. S.; Kozlowski, J. A.; Parker, D. J. Org. Chem. 
1984, 49, 3928. 
 (126) Cook, F. L.; Bowers, C. W.; Liotta, C. L. The Journal of Organic Chemistry 1974, 
39, 3416. 
86 
 
 (127) Tichenor, M. S.; MacMillan, K. S.; Stover, J. S.; Wolkenberg, S. E.; Pavani, M. 
G.; Zanella, L.; Zaid, A. N.; Spalluto, G.; Rayl, T. J.; Hwang, I.; Baraldi, P. G.; Boger, D. L. 
Journal of the American Chemical Society 2007, 129, 14092. 
 (128) Hayashi, H.; Nakanishi, K.; Brandon, C.; Marmur, J. J. Am. Chem. Soc. 1973, 
95, 8749. 
 (129) Wooley, K. L.; Hawker, C. J.; Frechet, J. M. J. J. Am. Chem. Soc. 1991, 113, 
4252. 
 (130) Kocienski, P. J.; Cernigliaro, G.; Feldstein, G. J. Org. Chem. 1977, 42, 353. 
 (131) Shaik, F. H.; Kar, G. K. Beilstein J. Org. Chem. 2009, 5, No. 47. 
 (132) Korapala, C. S.; Qin, J.; Friestad, G. K. Organic Letters 2007, 9, 4243. 
 (133) Nicolaou, K. C.; Snyder, S. A.; Giuseppone, N.; Huang, X.; Bella, M.; Reddy, 
M. V.; Rao, P. B.; Koumbis, A. E.; Giannakakou, P.; O'Brate, A. Journal of the American 
Chemical Society 2004, 126, 10174. 
 (134) Paquette, L. A.; Efremov, I. The Journal of Organic Chemistry 2004, 70, 510. 
 (135) Corey, E. J.; Wess, G.; Xiang, Y. B.; Singh, A. K. Journal of the American 
Chemical Society 1987, 109, 4717. 
 (136) Smith, S. G.; Winstein, S. Tetrahedron 1958, 3, 317. 
 (137) King, A. O.; Okukado, N.; Negishi, E.-i. Journal of the Chemical Society, Chemical 
Communications 1977, 683. 
 (138) Jensen, A. E.; Knochel, P. The Journal of Organic Chemistry 2001, 67, 79. 
 (139) Williams, D. R.; Kissel, W. S. Journal of the American Chemical Society 1998, 120, 
11198. 
 (140) Spino, C.; Granger, M.-C.; Tremblay, M.-C. Organic Letters 2002, 4, 4735. 
 (141) de Nooy, A. E. J.; Besemer, A. C.; van Bekkum, H. Tetrahedron 1995, 51, 8023. 
